NAMES OF COMPANIES ADDRESS PHONE NUMBERGenVec, Inc. 65 West Watkins Mill Road (240) 632-0740

Kirkegaard and Perry Laboratories, Inc. 910 Clopper Road (301) 948-7755Science Applications International Corp. (SAIC) Dr., Frederick MD 21703-7365 3016986188

Bioscience Super Array tive Way, Frederick, MD 21704 (301) 682-9200GeneDx 207 Perry Parkway (301) 519-2100

MiddleBrook Pharmaceuticals 425 Seneca Meadows Parkway (301) 944-6600Tetracore, Inc. 9901 Belward Campus Drive (240) 268-5400

NABI Biopharmaceuticals 12276 Wilkins Avenue (301) 770-3099EntreMed, Inc. 9640 Medical Center Drive (240) 864-2660

Avalon Pharmaceuticals, Inc. 358 Seneca Meadows Parkway (301) 556-9900Vanda Pharmaceuticals Inc. 9605 Medical Center Drive (240) 599-4500

BIOQUAL (3) 9600 Medical Center Drive (301) 251-2801Emergent BioSolutions Inc 2273 Research Boulevard (301) 795-1800

Pharmaceutical Preparation Mfg United Therapeutics , Silver Spring, MD 20910-4019 (301) 608-9292SGS Life Science Services - Clinical Research 12850 Middlebrook Road (877) 677-2667

Quality Biological, Inc. 7581 Lindbergh Drive (301) 840-9331Functional Genetics 708 Quince Orchard Road (240) 631-6790

Appropriate Technical Resources, Inc. P.O. Box 460 (301) 470-1267Sensors for Medicine and Science, Inc. 451 Seneca meadows Parkway (301) 515-7260

Sanofi-Aventis 1 Pennsylvania Ave. NW, D.C. (202) 682-0538BioServe 9000 Virginia Manor Road (301) 470-3362

Cato Research 9605 Medical Center Drive (301) 309-1260Bioscience International, Inc. 11333 Woodglen Drive (301) 231-7400

19300 Germantown Road (240) 686-7300Amaxa, Inc 205 Perry Parkway (240) 632-9110

Trevigen Gaithersburg, MD 20877-4131 (301) 560-4973Accelovance Suite 7 (240) 238-4900

GlycoMimetics, Inc. Gaithersburg, MD 20877 (240) 243-1201Cytomedix, Inc. 416 Hungerford Drive (240) 499-2680Transgenomic C, Gaithersburg, MD 20878-1704 (240) 631-2001

Calibrant Biosystems, Inc. 910 Clopper Road (301) 977-7900Alfagene Bioscience Inc. Pkwy, Gaithersburg, MD 20877

BIOCON, Inc. (2; Gaithersburg branch as well) 649 A Lofstrand Lane (301) 762-3202ExonHit Therapeutics, Inc. 217 Perry Parkway (240) 683-7070Applied Cell Sciences, Inc. 9430 Key West Avenue (240) 453-6331

Ani Lytics, Inc. 200 Girard Street (301) 921-0168The EMMES Corporation 401 North Washington Street (301) 251-1161

Theranostics Health 15010 Broschart Rd (301) 251-4443BioFactura, Inc. 9700 Great Seneca Highway (301) 315-8002

Lab Products, Inc. 11300 Rockville Pike (301) 468-0250AscentGene, Inc. 387 Technology Drive (240) 899-6538

BioFortis Inc. 9017 Red Branch Rd 1 to 4Bacilligen, Inc. 9700 Great Seneca Highway (301) 217-9525

Drug Development SVC Summit 15204 Omega Drive (240) 361-9105 1Doe & Ingalls of Maryland, LLC 8220 Patuxent Range Road (919) 598-1986

CoGenesys, Inc. 9410 Key West Avenue (240) 821-9000Creatv MicroTech, Inc 11609 Lake Potomac Drive (301) 983-1650

Correlogic Systems, Inc. (2; bethesda) 1405 Research Blvd (301) 795-170020/20 GeneSystems, Inc. 9430 Key West Ave (240) 453-6339

Adlyfe, Inc. (301) 424-8344

Qiagen Sciences, Inc. (3 in Gaithersburg)

Fisher BioServices 14665 Rothgeb Drive (301) 315-84602440 Research Blvd. (301) 990-0030

Protein Society Pike, Bethesda, MD 20814-3999 (301) 634-7240KamTek, Inc. 7858 Beechcraft Avenue (301) 208-2505

RNL Biostar, Inc. 9700 Great Seneca Hwy (240) 453-9393

Pharmacies & Drug Stores Amethyst Technologies Laurel, MD 20707-0000 (301)776-8461G-MED North America, Inc. 8070 Georgia Avenue (301) 495-0477

Advanced Biomimetic Sensors, Inc 12111 Parklawn Drive (301) 881-8174Advanced Genomics Technology Center (AGTC) 3007 Williams Drive (866) 599-2482

Advanced Product Enterprises LLC 4539 Metropolitan Court (301) 644-3913Alba Therapeutics, Inc 800 West Baltimore Street (410) 319-0780

Amarex Clinical Resevarch, LLC 20201 Century Boulevard (301) 528-7000Amulet Pharmaceutical, Inc. 9430 Key West Avenue (240) 499-2742

Arcion Therapeutics Inc 2400 Boston St (301) 325-3718BIOMERE LLC 7939 Sandalfoot Drive (301) 365-2493

Germantown, MD 20876TraumaCure, Inc. 7735 Old Georgetown Road (240) 497-0910

12th FloorAmerican Red Cross 15601 Crabbs Branch Way (301) 738-0575

VIRxSYS Corporation 200 Perry Parkway (301) 987-0480Suite 1A

STB Lifesaving Technologies, Inc. 15601 Crabbs Branch Way (301) 738-0424Rockville, MD 20855

Weinberg Medical Physics 5611 Roosevelt Street (301) 346-7944Bethesda, MD 20814

Tsumura USA Inc 1700 Rockville Pike (301) 468-1030Suite 360

Sirnaomics, Inc 401 Professional Drive (301) 977-6553Blue Torch Medical Technology 9700 Great Seneca Highway (508) 231-1080

Global Research Services, LLC (GRS) 2101 Gaither Rd. (301) 296-4742Suite 450

Global Drug Development Experts 910 17th Street, NW (202) 887-1690Suite 312

Individual Health Solutions, LLC 8323 Sharon Drive (301) 874-1797Suite 100

Innovative Biosensors, Inc. 15601 Crabbs Branch Way (301) 738-0604Rockville, MD 20855

Integrated BioTherapeutics Inc. 4539 Metropolitan Ct (301) 644-3919Frederick, MD 21704

DP Clinical, Inc. 1803 Research Boulevard (301) 294-6226Suite 404

Clarassance, Inc. 9700 Great Seneca Highway (301) 452-2899Suite 265

Cytimmune Sciences, Inc. 9640 Medical Center Drive (240) 864-2796Rockville, MD 20850

Foundation for The National Institutes of Health (FNIH) 9650 Rockville Pike (301) 443-1609Building 5

UMBI (Center for Advanced Research in Biotechnology) 9600 Gudelsky Drive (240) 314-6119Rockville, MD 20850

Panacea Pharmaceuticals, Inc. 207 Perry Parkway (240) 243-8000

Otsuka America Pharmaceutical, Inc. (2 branches)

Suite 2Mosaigen 9700 Great Seneca Highway (301) 792-4345

Rockville, MD 20850Neuralstem, Inc. 9700 Great Seneca Highway (301) 633-7709

Rockville, MD 20850Paragen, Inc. 1833 Baltimore Street, NW (202) 421-6892

Gaithersburg, MD 208795412QRxPharma Ltd. 155 Gibbs Street (301) 908-3086

Suite 510RAPID Laboratories, Inc. 15601 Crabbs Branch Way (301) 738-0772

Rockville, MD 20855Protein Potential, LLC 0 Medical Center Dr STE A209 (301)-770-5554

Rockville, MD 20850PlantVax, Inc 9700 Great Seneca Highway (240) 453-6247

Suite 182One MedImmune Way (301) 398-0000

Gaithersburg, MD 20878MaxCyte, Inc. 22 Firstfield Road (301) 944-1700

Suite 250Global Drug Development Experts 910 17th Street, NW (202) 887-1690

Gaithersburg, MD 20878Keygene, Inc. vation Center, 155 Gibbs Street (240) 205-7083

Suite 405KAI Research, Inc. 6001 Montrose Road (301) 770-2730

Suite 920Gaithersburg, MD 20879

MedImmune, Inc. (8 in MD; 1 in DC)

WEBSITE NUMBER OF STAFF109807070706765605756505049302525242020202020191917171613111110

http://www.alfagene.com/ 999977555

http://www.ascentgene.com/ 5444444444

http://www.genvec.comhttp://www.kpl.comhttp://www.saic.comwww.superarray.comhttp://www.genedx.comhttp://www.MiddleBrookPharma.comhttp://www.tetracore.comhttp://www.nabi.comhttp://www.entremed.comhttp://www.avalonrx.com/http://www.vandapharm.comhttp://www.bioqual.comhttp://www.emergentbiosolutions.comhttp://www.unither.com/UnitherHome.aspxhttp://www.sgs.com/lifesciencehttp://www.qualitybiological.comhttp://www.functional-genetics.comhttp://www.atrbiotech.comhttp://www.s4ms.comhttp://www.sanofi-aventis.ushttp://www.bioserve.com/http://www.cato.comhttp://www.biosci-intl.comhttp://www.qiagensciences.comhttp://www.amaxa.comwww.trevigen.comhttp://www.accelovance.com/index.htmhttp://www.glycomimetics.comhttp://www.cytomedix.com/www.transgenomic.comhttp://www.calibrant.com

http://www.bioconinc.comhttp://www.exonhit.comhttp://www.appliedcellsci.comhttp://www.latanet.com/e-source/!VENDORS.AD/!ANILYTI.HTMhttp://pub.emmes.comhttp://www.theranosticshealth.com/http://www.biofactura.comhttp://www.labproductsinc.com

http://www.biofortis.comhttp://www.bacilligen.com/home.aspxhttp://www.summitdrug.comhttp://www.doeingalls.comhttp://www.cogenesys.comhttp://www.creatvmicrotech.comhttp://www.correlogic.comhttp://www.2020gene.comhttp://www.adlyfe.com

4444443

http://www.fisherbioservices.comhttp://www.otsuka.comhttp://www.proteinsociety.org/http://www.kamtekinc.comhttp://www.rnlbiostar.comhttp://www.amethysttech.com/news.htmhttp://www.gmed.fr/index_en.asp

http://www.agtcenter.comhttp://www.ape-bio.comhttp://www.albatherapeutics.comhttp://www.amarexcro.comhttp://www.amuletpharma.com

http://www.biomere.com

http://www.traumacure.com

http://www.redcross.org

http://www.virxsys.com

http://www.stbbandage.com

http://www.tsumura.co.jp

http://www.sirnaomics.comhttp://www.bluetorchmed.com/http://www.grs-cro.com

http://www.gddexperts.com

http://www.signaturesupplements.com

http://www.innovativebiosensors.com

http://www.ibtinc-usa.com

http://www.dpclinical.com

http://www.clarassance.com

http://www.cytimmune.com

http://www.fnih.org

http://www.umbi.umd.edu

http://www.panaceapharma.com

http://www.mosaigen.com

http://www.neuralstem.com

http://www.para-gen.com/

http://www.qrxpharma.com

http://www.rapidpharma.com

http://www.proteinpotential.com

http://www.medimmune.com

http://www.maxcyte.com

http://www.gddexperts.com

http://www.keygene.com

http://www.kai-research.com

ANNUAL SALES EMAIL DESCRIPTION OF INDUSTRY$18,923,000 GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

$20 to 50 million KPL is a supplier of reagents and kits (i.e. complete systems) used for detection of proteins and nucleic acids across a wide spectrum of assay platforms including ELISA, western, Northern and Southern Blot and in Situ analysis.10 to 20 million SAIC provides technical and analytical contract support for biomedical product development. Their operations contain biomedical scientists, chemists, biomedical engineers, cost analysts, data base developers, and graphic, publications, and meeting support staff. Business focus is support to biomedical product development, specially FDA regulatory affairs regulatory submittals and Good Manufacturing Practices.

$20 to 50 million$10 to 20 million GeneDx provides rapid molecular diagnosis of rare hereditary disorders, serving the clinical needs of patients, physicians genetic counselors and researchers worldwide. We offer mutation detection, genotyping, carrier detection and prenatal diagnosis in over 130 diseases. GeneDx specializes in translating new genetic tests from the research laboratory to the medical community.

$16,848,000 MiddleBrook Pharmaceuticals is a therapeutically-focused biopharmaceutical company, developing novel therapeutics for infectious diseases.$20 to 50 million Tetracore is a biotechnology R&D and product company whose mission is to create and develop highly innovative diagnostic reagents and assays for infectious diseases and bio-terrorism threat agents. We focus on veterinary, domestic preparedness, clinical, antibody and ELISA products.$20 to 50 million Nabi is developing breakthrough anti-infective products, vaccines and specific polyclonal antibodies to address life-threatening bacterial and viral diseases and their associated complications.

$6,894,000 EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMedâ s drug candidates target disease cells and the blood vessels that nourish them. The companyâ s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammationâ processes that are vital to the progression of cancer and other diseases. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.�� �� ��$2,724,000 A research and development company focusing on developing theraputic treatments for cancer through genomics.

$80,038,000 IT exe.: Gunther Birznieks$21,869,000 BIOQUAL has commercial and government contracts providing holding and technical services using animal models ranging from mice to non-human primates. Applications include breeding, immunological and/or disease applications.

$20 to 50 million (note: website looks like Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple missionâ��to protect life. The company develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the bodyâ��s immune system to prevent or treat disease. The companyâ��s biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThraxà ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The companyâ��s commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.�$210,943,000 IT Exec.: Mr. Shola Oyewole

SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With over 1,300 employees and 2,000 trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries. SGS' state of the art facilities include: three Phase I units with a total of 162 beds, four bioanalytical labs, and Phase II-IV clinical trial management offices across Europe, North America & Asia. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can significantly improve client's drug development timelines and decision-making processes.$10 to 20 million Quality Biological manufacturers and sells biological reagents and cell culture media. They also provide facilities management and contract support to government and private institutions.

Funtional Genetics Inc. is a growing biotechnology comapny which is a privately held firm focused on developing level novel drugs for infectious diseases including: Influenza, HIV, Ebola, and Hemorrhagic fever.10 to 20 million Appropriate Technical Resources, Inc. has been serving the scientific research community for over 25 years in sales, service, and manufacturing. ATR currently manufactures the hybridization ovens for Affymetrix as well as small accessory products for research. ATR is the US distributor for Infors AG in Switzerland and manufactures the unique stackable cabinet shakers for growth of bacteria, yeast, insect cells, and mammalian cells. ATR promotes the Infors line of fermenters in the US. ATR Biotech, our CA company is located in Fremont and supports customers with sales and service.2.5 to 5 million Sensors for Medicine and Science provides sensing technologies for the detection and measurement of molecules of significant commercial interest. The Company's lead product development effort is a tiny implantable glucose sensor for diabetics.2.5 to 5 million10 to 20 million info@bioserve.com BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.2.5 to 5 million Cato Research is an independent, full-service contract research and development organization with international resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics, and medical devices to market.

Bioscience International, Inc. provides microbiologists with microbial air samplers, automated medium preparation equipment, autoclaves, environmental monitoring tools and NIST traceable calibration services.$500,000 (note: prb logging on webQiagen is the world's leading provider of innovative enabling technologies for the purification and handling of DNA and RNA.

2.5 to 5 million (note: email forms on webA biotech firm located in Gaithersburg, MD specializing in gene transfer technology.$5 to 10 million info@trevigen.com2.5 to 5 million info@accelovance.com

GlycoMimetics is a biotechnology company developing novel therapautics based on glycobiology. Our focus is on inflammation and infectious disease.$1,943,000 info@cytomedix.com Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for use on wounds and other applications. The current offering is the AutoloGel(tm) System, a process that utilizes an autologous platelet gel composed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.

$5 to 10 million info@transgenomic.comCalibrant Biosystems is pioneering the discovery of novel proteins targets and biomarkers for the treatment of cancer. Calibrant's uniquely targeted approach to biomarker discovery is based on a proprietary technology platform (Gemini) which enables rapid, comprehensive, and quantitative protein profiling from limited microdissected tissue specimens. The company engages in discovery and developmen partnerships with pharmaceutical and biotechnology companies, and outlicensing of novel drug targets and diagnostic markers developed through discovery partnerships with leading clinical researchers.

info@alfagene.comBIOCON, Inc. is a research laboratory servicing the biomedical and biotechnology communities and specializing in animal related services and equipped to provide all phases of animal research, transgen breeding, and custom antibody production.ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005Discover and validate novel drug-discovery targets, with particular emphasis on GPCR targets. Also supplies a variety of products and services (such as large-scale cell culture and large-scale transfections) to the drug discovery community.Ani Lytics, Inc. performs hematologic and clinical chemistry testing, custom method development, and consultation supporting biomedical research.

$500,000 to 1 million The EMMES Corporation is a contract research organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical support for clinical research, including standard operating procedure (SOP) and protocol development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the culmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease processes and potential therapies.info2@theranosticshealt Headquartered in Rockville, Maryland, THX is a start-up life science Company with a singular focus: enabling the promise of personalized therapy to become a reality. Theranostics is the ability to use a diagnostic biomarker(s) for selecting and tailoring therapy. THX is focusing on oncology, diabetes, inflammation, obesity, cardiovascular disease and infectious disease indications.

$1 to 2.5 million BioFactura is committed to bringing innovative science, advanced process technology, and total quality services to the pioneers of biologic medicine. We offer a broad range of process development and manufacturing services to customers and partners seeking to bring promising therapeutics, vaccines, and diagnostics to the commercial markets. In addition, BioFactura is utilizing its extensive experience to develop technologies that will add value to biopharmaceuticals as they move from discovery through the clinic and into the marketplace.$1 to 2.5 million Lab Products is the leading manufacturer of quality products for the biomedical research community. Products include an extensive line of equipment for the housing of laboratory animals as well as a variety of environmental control systems.

info@ascentgene.com AscentGene, Inc. is a developing stage biotechnology company that uses its proprietary innovative technologies to develop, manufacture, and market a new generation of diagnostic devices, novel drugs for human diseases and other bio-products for research, drug development, and other medical applications. AscentGene is affiliated with the Technology Advanced Program (TAP) at the University of Maryland at College Park.

Bacilligen is an NIH-funded Maryland corporation whose primary focus is the development of vaccine platform technologies for AIDS and biodefense/emergency preparedness. The company is also pursuing development of a next generation protein manufacturing technology with specific advantages in emergency preparedness. Finally, we are also pursuing a treatment for bladder cancer.5 to 10 million Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.

$500,000 to 1 million Doe & Ingalls of Maryland is a chemical service provider who helps biotechnology and electronic companies build reliable chemical supply chains that meet their compliance, risk and operational goals. We supply brand name chemicals from a worldwide network of quality manufacturers and complement these products with in-house services such as specialty sourcing, lot control, onsite sampling, temperature-controlled storage, chemical management and risk mitigation planning. The company has four locations on the east coast, including Jessup, Maryland; Richmond, Virginia; Durham, North Carolina; and Tampa, Florida. Our service centers are GMP-compliant and operate under proven ISO 9001: 2000 procedures.$ 5 to 10 million

Creatv MicroTech develops diagnostic instruments, devices and research tools in the following categories: · Ultra-sensitive fluorometer/luminometer platforms for testing of proteins, bacteria, viruses, cells, DNA, etc. · Immunoassays combined with PCR to detect pathogens in food, water and the environment such as E. coli, Salmonella, anthrax spores, etc. · Antimortem test for Prion Disease · Diagnostic test for aggressive versus indolent chronic lymphocytic leukemia (CLL) · Immunoassay combined with enzymatic assay to detect botulinum toxin. · High-aspect-ratio microfabrication of metal and composites. Applications include x-ray anti-scatter grids, nuclear collimators, high-density cell culture plates, etc.$ 5 to 10 million Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery, drug response monitoring, bio-security and other applications has been published in 12 peer-reviewed journals.

20/20 GeneSystems, Inc. is a biotechnology company that has developed and is now selling an innovative proteomics product line that provides drug companies and life scientists with a digital "snapshot" of the protein signaling pathways in disease samples. The proteomic snapshot allows drug therapies to be disigned and ultimately personalized to patients based on the protein profiles of the diseases.Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

mtucker@genvec.comBusinessdevelopment@kpl.com

genedx@genedx.com

mkalnik@nabi.com (Matthew Kalnik, Ph.D.)tomb@entremed.com (Thomas Bliss)

webmaster@unither.com

info@qualitybiological.cominfo@functional-genetics.com

With 2006 net sales of 28.4 billion euros and an estimated 100,000 employees worldwide, sanofi-aventis is one of the world's largest pharmaceutical companies. Global headquarters are located in Paris, France and U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis U.S. employs approximately 16,000 employees, with 8,000 sales professionals. The U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis' R&D organization is comprised of approximately 17,500 scientists working in over 28 research centers around the world. Sanofi-aventis' current portfolio includes over 50 compounds. Sanofi-aventis has 7 major therapeutic areas: Cardiology, Thrombosis, Oncology, Internal Medicine, Metabolic disorders, diseases of the Central Nervous System and Vaccines.

info@cato.com

webmaster@glycomimetics.com

bioconinfo@bioconinc.com

webmaster@emmes.com

$1 to 2.5 million Fisher BioServices provides biomedical services including storage$500, 000 to 1 million Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

$500,000 to 1 million kamtekinc@aol.com KamTek promotes investigations in systems biology by offering Genomics, Proteomics and Glycomics solutions in the form of: (1) Microarray Bio-Chip Services such as Microarray Printing, High Throughput Immunological or Gene Expression Assays and other Molecular Biology Services; (2) Cell Culture; and (3) Bio-Repository Services.

$500,000 to 1 million$500,000 to 1 million

Advance Genomics is a biotechnology company organized in 2007 to address the research and validation needs in the human and animal biotech industry. The company uses the Illumina microarray platform to provide SNP genotyping, LOH and CNV studies, and gene expression analyses as well as experimental design consultation and data analysis services. Our scientists are experienced in developing custom molecular assays for clients using either microarray or multiplex PCR configurations. The company also provides genetic characterization and pathogen testing services of tissue samples and cell lines. The laboratory is located in Fairfax, Virginia just outside Washington, DC.

Alba Therapeutics Corporation is a clinical stage biopharmaceutical company focused on the discovery, development, production and marketing of pharmaceuticals for the treatment of inflammatory and immune-related diseases.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.Arcion Therapeutics Inc. is a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain. Arcion has a pipeline of products being developed for the treatment of painful diabetic neuropathy, post-herpetic neuralgia and other forms of moderate and severe pain. The company is located in Baltimore, Maryland.BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

Housed in the Jerome H. Holland Laboratory for the Biomedical Sciences in Rockville, Maryland, the Red Cross biomedical R&D program investigates transfusion-transmissible infections and facilitates improvements in blood collection, processing, and provision. The program's researchers include internationally respected experts in transfusion technology, transfusion-transmitted diseases, and blood component biology.

VIRxSYS Corporation is an early-stage biotechnology company developing products based on novel gene therapy platforms under the SmartVector (TM) trade name. Potential products include therapeutic treatments and vaccines for a variety of diseases

inweinberg@gmail.com STB Lifesaving Technologies, Inc. was founded to support the research, development, and commercialization of enhanced hemostatic technologies, encompassing a broad range of products with the ability to control bleeding. STB, Inc. is currently focused on the development and commercialization of novel FAST dressing products designed to arrest severe hemorrhages. The widespread medical applications of the Company's dressing products will dramatically reduce fatalities caused by blood loss resulting from trauma, surgery or pathologic conditions.

WMP's staff previously started two companies in molecular breast imaging. We are now engaged in cooperative projects with local and international academic groups, focused on high resolution MRI and molecular imaging.

info-office@sirnaomics.com

info@grs-cro.com

Global Research Services (GRS) is a full-service clinical trials management organization with a specialized focus on the development of cardiovascular and metabolic drugs and devices. The staff of GRS has been serving the sponsors of Phase I-IV research for over 20 years. Headquartered in Rockville, Maryland, GRS is a founding member of the Association of Clinical Research Organization (ACRO) and operates additional offices in Canada, China, Germany and Poland.

gsandman@signaturesupGlobal Drug Development Experts specializes in partnering with Pharmaceutical, Biotechnology and Medical Devices firms to design

Individualized nutrition analysis and nutrition solution.

DP Clinical (DPC) is a full service contract research organization (CRO) located in the heart of the I-270 Technology Corridor in Rockville, Maryland. Since 1994 DPC, a minority-owned business, has been serving pharmaceutical, biotechnology and medical device clients and providing clients with project management, monitoring, data management, data analysis, quality assurance and regulatory for Phase I – IV clinical trials. DPC has built a strong reputation for high standards of quality, data integrity, cost-effectiveness and client satisfaction.

(note: email forms on webClarassance is a privately held Delaware Corporation formed exclusively to develop novel biopharmaceutical candidates derived from the secretoglobin family of proteins, initially targeting inflammatory and immune diseases. More specifically, the company will advance the clinical development of its lead candidate, called Claragen, in respiratory disease. The company will take Claragen through Phase 2a and 2b clinical trials to demonstrate efficacy in patients with chronic nasal rhinitis, sinusitis, and nasal polyposis, a significant value-driving milestone. The company will operate in virtual mode, utilizing consultants and contract research organizations as needed, and maintaining a small staff and office in Rockville, MD, through completion of this milestone.

(note: email forms on webCytImmune is focused on developing colloidal gold as a targeted drug/gene delivery system. The safe, effective delivery of TNF bound to colloidal gold for cancer treatment demonstrates the utility of this delivery system.

The Foundation for the National Institutes of Health supports the mission of the Natioanl Institutes of Health, the premier research organization in the world and the steward of our nation's investment in medical discovery. The Foundation for NIH creates public-private partnerships to seek solutions for cancer, heart disease, Alzheimer's, diabetes, depresstion and other illnesses, as well as help to develop, improve and deliver life-saving vaccines.

The Center for Advanced Research in Biotechnology (CARB) is a research center of the University of Maryland Biotechnology Institute (UMBI). CARB is staffed by collaborating scientists from UMBI, the National Institute of Standards and Technology (NIST) and UMBI's Center for Biosystems Research (CBR) with aim of integrating information from molecular and biological research on complex biological systems. Our facilities are located on the recently expanded (UMBI) Shady Grove campus of the University System of Maryland.

(note: new website; 'comiPanacea Pharmaceuticls, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The company's product development strategy is based on novel therapeutic agents and approaches for cancer diagnosis and treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies.

Info.FisherBioServices@Thermofisher.comwebmaster@otsuka.comcyablonski@proteinsociety.org

gmedna@lne-gmed.com

foundation@fnih.org

Neuralstem is a biotechnology company focused on developing and commercializing human neural stem cell technology in the field of regenerative medicine. Co. focuses primarily on the field of Cell Therapy, which involves the development and commercialization of treatments based on transplanting human neural stem cells.

(note: goto website for email form)

(note: goto website for emQRxPharma is a late-stage specialty pharmaceutical company with repositioned drugs in clinical development for the treatment of pain and neurodegenerative diseases. The Company is listed on the Australian Securities Exchange (ASX) as "QRX", and is headquartered in Sydney, Australia. Clinical trials are being conducted in the US, with offices in Rockville, MD.

RAPID Laboratories, Inc. is a drug discovery and development company whose purpose is the development of small receptor active peptides for the treatment of HIV/AIDS, development of an HIV vaccine, and the creation of novel anti-inflammatory peptides useful in the treatment of chronic inflammatory and degenerative diseases for which few or no effective treatments exist.

Protein Potential provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids for research and development. Protein Potential also provides production clone generation; fermentation optimization and process development; development of analytical assays; development of bulk and drug product lot release assays; including potency, immunogenicity and antigenicity; studies of the immunogenicity of vaccine candidates; documentation; and the technologicial know-how to transition therapeutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.

ProCell Corporation, was founded in 2000 to develop and commercialize discoveries made for the pre- and post-exposure treatment for nerve agent exposure and the treatment, diagnosis, and control of global infectious diseases of which HIV is the initial target.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

Global Drug Development Experts specializes in partnering with Pharmaceutical, Biotechnology and Medical Devices firms to design

Keygene develops and applies novel technologies in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design.

KAI's staff of over 70 full time employees includes senior project managers, physicians, Ph.D. researchers, clinical research associates (CRAs), information technology experts, database and web designers, statistical programmers, data managers, pharmacologists, and research assistants.

irgarr@neuralstem.net (Richard Garr)

irgarr@neuralstem.net

infobusdev@medimmune.com

info@maxcyte.com

info@gddexperts.com

info@gddexperts.com

kai@kai-research.com

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��KPL is a supplier of reagents and kits (i.e. complete systems) used for detection of proteins and nucleic acids across a wide spectrum of assay platforms including ELISA, western, Northern and Southern Blot and in Situ analysis.SAIC provides technical and analytical contract support for biomedical product development. Their operations contain biomedical scientists, chemists, biomedical engineers, cost analysts, data base developers, and graphic, publications, and meeting support staff. Business focus is support to biomedical product development, specially FDA regulatory affairs regulatory submittals and Good Manufacturing Practices.

GeneDx provides rapid molecular diagnosis of rare hereditary disorders, serving the clinical needs of patients, physicians genetic counselors and researchers worldwide. We offer mutation detection, genotyping, carrier detection and prenatal diagnosis in over 130 diseases. GeneDx specializes in translating new genetic tests from the research laboratory to the medical community.MiddleBrook Pharmaceuticals is a therapeutically-focused biopharmaceutical company, developing novel therapeutics for infectious diseases.Tetracore is a biotechnology R&D and product company whose mission is to create and develop highly innovative diagnostic reagents and assays for infectious diseases and bio-terrorism threat agents. We focus on veterinary, domestic preparedness, clinical, antibody and ELISA products.Nabi is developing breakthrough anti-infective products, vaccines and specific polyclonal antibodies to address life-threatening bacterial and viral diseases and their associated complications.EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMedâ s drug candidates target disease cells and the blood vessels that nourish them. The companyâ s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammationâ processes that are vital to the progression of cancer and other diseases. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.�� �� ��A research and development company focusing on developing theraputic treatments for cancer through genomics.

BIOQUAL has commercial and government contracts providing holding and technical services using animal models ranging from mice to non-human primates. Applications include breeding, immunological and/or disease applications.Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple missionâ��to protect life. The company develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the bodyâ��s immune system to prevent or treat disease. The companyâ��s biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThraxà ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The companyâ��s commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.�

SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With over 1,300 employees and 2,000 trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries. SGS' state of the art facilities include: three Phase I units with a total of 162 beds, four bioanalytical labs, and Phase II-IV clinical trial management offices across Europe, North America & Asia. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can significantly improve client's drug development timelines and decision-making processes.Quality Biological manufacturers and sells biological reagents and cell culture media. They also provide facilities management and contract support to government and private institutions.Funtional Genetics Inc. is a growing biotechnology comapny which is a privately held firm focused on developing level novel drugs for infectious diseases including: Influenza, HIV, Ebola, and Hemorrhagic fever.Appropriate Technical Resources, Inc. has been serving the scientific research community for over 25 years in sales, service, and manufacturing. ATR currently manufactures the hybridization ovens for Affymetrix as well as small accessory products for research. ATR is the US distributor for Infors AG in Switzerland and manufactures the unique stackable cabinet shakers for growth of bacteria, yeast, insect cells, and mammalian cells. ATR promotes the Infors line of fermenters in the US. ATR Biotech, our CA company is located in Fremont and supports customers with sales and service.Sensors for Medicine and Science provides sensing technologies for the detection and measurement of molecules of significant commercial interest. The Company's lead product development effort is a tiny implantable glucose sensor for diabetics.

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.Cato Research is an independent, full-service contract research and development organization with international resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics, and medical devices to market.Bioscience International, Inc. provides microbiologists with microbial air samplers, automated medium preparation equipment, autoclaves, environmental monitoring tools and NIST traceable calibration services.Qiagen is the world's leading provider of innovative enabling technologies for the purification and handling of DNA and RNA.A biotech firm located in Gaithersburg, MD specializing in gene transfer technology.

GlycoMimetics is a biotechnology company developing novel therapautics based on glycobiology. Our focus is on inflammation and infectious disease.Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for use on wounds and other applications. The current offering is the AutoloGel(tm) System, a process that utilizes an autologous platelet gel composed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.

Calibrant Biosystems is pioneering the discovery of novel proteins targets and biomarkers for the treatment of cancer. Calibrant's uniquely targeted approach to biomarker discovery is based on a proprietary technology platform (Gemini) which enables rapid, comprehensive, and quantitative protein profiling from limited microdissected tissue specimens. The company engages in discovery and developmen partnerships with pharmaceutical and biotechnology companies, and outlicensing of novel drug targets and diagnostic markers developed through discovery partnerships with leading clinical researchers.

BIOCON, Inc. is a research laboratory servicing the biomedical and biotechnology communities and specializing in animal related services and equipped to provide all phases of animal research, transgen breeding, and custom antibody production.ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005Discover and validate novel drug-discovery targets, with particular emphasis on GPCR targets. Also supplies a variety of products and services (such as large-scale cell culture and large-scale transfections) to the drug discovery community.Ani Lytics, Inc. performs hematologic and clinical chemistry testing, custom method development, and consultation supporting biomedical research.The EMMES Corporation is a contract research organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical support for clinical research, including standard operating procedure (SOP) and protocol development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the culmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease processes and potential therapies.Headquartered in Rockville, Maryland, THX is a start-up life science Company with a singular focus: enabling the promise of personalized therapy to become a reality. Theranostics is the ability to use a diagnostic biomarker(s) for selecting and tailoring therapy. THX is focusing on oncology, diabetes, inflammation, obesity, cardiovascular disease and infectious disease indications.BioFactura is committed to bringing innovative science, advanced process technology, and total quality services to the pioneers of biologic medicine. We offer a broad range of process development and manufacturing services to customers and partners seeking to bring promising therapeutics, vaccines, and diagnostics to the commercial markets. In addition, BioFactura is utilizing its extensive experience to develop technologies that will add value to biopharmaceuticals as they move from discovery through the clinic and into the marketplace.Lab Products is the leading manufacturer of quality products for the biomedical research community. Products include an extensive line of equipment for the housing of laboratory animals as well as a variety of environmental control systems.AscentGene, Inc. is a developing stage biotechnology company that uses its proprietary innovative technologies to develop, manufacture, and market a new generation of diagnostic devices, novel drugs for human diseases and other bio-products for research, drug development, and other medical applications. AscentGene is affiliated with the Technology Advanced Program (TAP) at the University of Maryland at College Park.

Bacilligen is an NIH-funded Maryland corporation whose primary focus is the development of vaccine platform technologies for AIDS and biodefense/emergency preparedness. The company is also pursuing development of a next generation protein manufacturing technology with specific advantages in emergency preparedness. Finally, we are also pursuing a treatment for bladder cancer.Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.Doe & Ingalls of Maryland is a chemical service provider who helps biotechnology and electronic companies build reliable chemical supply chains that meet their compliance, risk and operational goals. We supply brand name chemicals from a worldwide network of quality manufacturers and complement these products with in-house services such as specialty sourcing, lot control, onsite sampling, temperature-controlled storage, chemical management and risk mitigation planning. The company has four locations on the east coast, including Jessup, Maryland; Richmond, Virginia; Durham, North Carolina; and Tampa, Florida. Our service centers are GMP-compliant and operate under proven ISO 9001: 2000 procedures.

Creatv MicroTech develops diagnostic instruments, devices and research tools in the following categories: · Ultra-sensitive fluorometer/luminometer platforms for testing of proteins, bacteria, viruses, cells, DNA, etc. · Immunoassays combined with PCR to detect pathogens in food, water and the environment such as E. coli, Salmonella, anthrax spores, etc. · Antimortem test for Prion Disease · Diagnostic test for aggressive versus indolent chronic lymphocytic leukemia (CLL) · Immunoassay combined with enzymatic assay to detect botulinum toxin. · High-aspect-ratio microfabrication of metal and composites. Applications include x-ray anti-scatter grids, nuclear collimators, high-density cell culture plates, etc.Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery, drug response monitoring, bio-security and other applications has been published in 12 peer-reviewed journals.20/20 GeneSystems, Inc. is a biotechnology company that has developed and is now selling an innovative proteomics product line that provides drug companies and life scientists with a digital "snapshot" of the protein signaling pathways in disease samples. The proteomic snapshot allows drug therapies to be disigned and ultimately personalized to patients based on the protein profiles of the diseases.Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

With 2006 net sales of 28.4 billion euros and an estimated 100,000 employees worldwide, sanofi-aventis is one of the world's largest pharmaceutical companies. Global headquarters are located in Paris, France and U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis U.S. employs approximately 16,000 employees, with 8,000 sales professionals. The U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis' R&D organization is comprised of approximately 17,500 scientists working in over 28 research centers around the world. Sanofi-aventis' current portfolio includes over 50 compounds. Sanofi-aventis has 7 major therapeutic areas: Cardiology, Thrombosis, Oncology, Internal Medicine, Metabolic disorders, diseases of the Central Nervous System and Vaccines.

Fisher BioServices provides biomedical services including storageOtsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

KamTek promotes investigations in systems biology by offering Genomics, Proteomics and Glycomics solutions in the form of: (1) Microarray Bio-Chip Services such as Microarray Printing, High Throughput Immunological or Gene Expression Assays and other Molecular Biology Services; (2) Cell Culture; and (3) Bio-Repository Services.

Advance Genomics is a biotechnology company organized in 2007 to address the research and validation needs in the human and animal biotech industry. The company uses the Illumina microarray platform to provide SNP genotyping, LOH and CNV studies, and gene expression analyses as well as experimental design consultation and data analysis services. Our scientists are experienced in developing custom molecular assays for clients using either microarray or multiplex PCR configurations. The company also provides genetic characterization and pathogen testing services of tissue samples and cell lines. The laboratory is located in Fairfax, Virginia just outside Washington, DC.

Alba Therapeutics Corporation is a clinical stage biopharmaceutical company focused on the discovery, development, production and marketing of pharmaceuticals for the treatment of inflammatory and immune-related diseases.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.Arcion Therapeutics Inc. is a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain. Arcion has a pipeline of products being developed for the treatment of painful diabetic neuropathy, post-herpetic neuralgia and other forms of moderate and severe pain. The company is located in Baltimore, Maryland.BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

Housed in the Jerome H. Holland Laboratory for the Biomedical Sciences in Rockville, Maryland, the Red Cross biomedical R&D program investigates transfusion-transmissible infections and facilitates improvements in blood collection, processing, and provision. The program's researchers include internationally respected experts in transfusion technology, transfusion-transmitted diseases, and blood component biology.

VIRxSYS Corporation is an early-stage biotechnology company developing products based on novel gene therapy platforms under the SmartVector (TM) trade name. Potential products include therapeutic treatments and vaccines for a variety of diseases

STB Lifesaving Technologies, Inc. was founded to support the research, development, and commercialization of enhanced hemostatic technologies, encompassing a broad range of products with the ability to control bleeding. STB, Inc. is currently focused on the development and commercialization of novel FAST dressing products designed to arrest severe hemorrhages. The widespread medical applications of the Company's dressing products will dramatically reduce fatalities caused by blood loss resulting from trauma, surgery or pathologic conditions.

WMP's staff previously started two companies in molecular breast imaging. We are now engaged in cooperative projects with local and international academic groups, focused on high resolution MRI and molecular imaging.

Global Research Services (GRS) is a full-service clinical trials management organization with a specialized focus on the development of cardiovascular and metabolic drugs and devices. The staff of GRS has been serving the sponsors of Phase I-IV research for over 20 years. Headquartered in Rockville, Maryland, GRS is a founding member of the Association of Clinical Research Organization (ACRO) and operates additional offices in Canada, China, Germany and Poland.

Global Drug Development Experts specializes in partnering with Pharmaceutical, Biotechnology and Medical Devices firms to design

DP Clinical (DPC) is a full service contract research organization (CRO) located in the heart of the I-270 Technology Corridor in Rockville, Maryland. Since 1994 DPC, a minority-owned business, has been serving pharmaceutical, biotechnology and medical device clients and providing clients with project management, monitoring, data management, data analysis, quality assurance and regulatory for Phase I – IV clinical trials. DPC has built a strong reputation for high standards of quality, data integrity, cost-effectiveness and client satisfaction.

Clarassance is a privately held Delaware Corporation formed exclusively to develop novel biopharmaceutical candidates derived from the secretoglobin family of proteins, initially targeting inflammatory and immune diseases. More specifically, the company will advance the clinical development of its lead candidate, called Claragen, in respiratory disease. The company will take Claragen through Phase 2a and 2b clinical trials to demonstrate efficacy in patients with chronic nasal rhinitis, sinusitis, and nasal polyposis, a significant value-driving milestone. The company will operate in virtual mode, utilizing consultants and contract research organizations as needed, and maintaining a small staff and office in Rockville, MD, through completion of this milestone.

CytImmune is focused on developing colloidal gold as a targeted drug/gene delivery system. The safe, effective delivery of TNF bound to colloidal gold for cancer treatment demonstrates the utility of this delivery system.

The Foundation for the National Institutes of Health supports the mission of the Natioanl Institutes of Health, the premier research organization in the world and the steward of our nation's investment in medical discovery. The Foundation for NIH creates public-private partnerships to seek solutions for cancer, heart disease, Alzheimer's, diabetes, depresstion and other illnesses, as well as help to develop, improve and deliver life-saving vaccines.

The Center for Advanced Research in Biotechnology (CARB) is a research center of the University of Maryland Biotechnology Institute (UMBI). CARB is staffed by collaborating scientists from UMBI, the National Institute of Standards and Technology (NIST) and UMBI's Center for Biosystems Research (CBR) with aim of integrating information from molecular and biological research on complex biological systems. Our facilities are located on the recently expanded (UMBI) Shady Grove campus of the University System of Maryland.

Panacea Pharmaceuticls, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The company's product development strategy is based on novel therapeutic agents and approaches for cancer diagnosis and treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies.

Neuralstem is a biotechnology company focused on developing and commercializing human neural stem cell technology in the field of regenerative medicine. Co. focuses primarily on the field of Cell Therapy, which involves the development and commercialization of treatments based on transplanting human neural stem cells.

QRxPharma is a late-stage specialty pharmaceutical company with repositioned drugs in clinical development for the treatment of pain and neurodegenerative diseases. The Company is listed on the Australian Securities Exchange (ASX) as "QRX", and is headquartered in Sydney, Australia. Clinical trials are being conducted in the US, with offices in Rockville, MD.

RAPID Laboratories, Inc. is a drug discovery and development company whose purpose is the development of small receptor active peptides for the treatment of HIV/AIDS, development of an HIV vaccine, and the creation of novel anti-inflammatory peptides useful in the treatment of chronic inflammatory and degenerative diseases for which few or no effective treatments exist.

Protein Potential provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids for research and development. Protein Potential also provides production clone generation; fermentation optimization and process development; development of analytical assays; development of bulk and drug product lot release assays; including potency, immunogenicity and antigenicity; studies of the immunogenicity of vaccine candidates; documentation; and the technologicial know-how to transition therapeutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.

ProCell Corporation, was founded in 2000 to develop and commercialize discoveries made for the pre- and post-exposure treatment for nerve agent exposure and the treatment, diagnosis, and control of global infectious diseases of which HIV is the initial target.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

Global Drug Development Experts specializes in partnering with Pharmaceutical, Biotechnology and Medical Devices firms to design

Keygene develops and applies novel technologies in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design.

KAI's staff of over 70 full time employees includes senior project managers, physicians, Ph.D. researchers, clinical research associates (CRAs), information technology experts, database and web designers, statistical programmers, data managers, pharmacologists, and research assistants.

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��KPL is a supplier of reagents and kits (i.e. complete systems) used for detection of proteins and nucleic acids across a wide spectrum of assay platforms including ELISA, western, Northern and Southern Blot and in Situ analysis.SAIC provides technical and analytical contract support for biomedical product development. Their operations contain biomedical scientists, chemists, biomedical engineers, cost analysts, data base developers, and graphic, publications, and meeting support staff. Business focus is support to biomedical product development, specially FDA regulatory affairs regulatory submittals and Good Manufacturing Practices.

GeneDx provides rapid molecular diagnosis of rare hereditary disorders, serving the clinical needs of patients, physicians genetic counselors and researchers worldwide. We offer mutation detection, genotyping, carrier detection and prenatal diagnosis in over 130 diseases. GeneDx specializes in translating new genetic tests from the research laboratory to the medical community.

Tetracore is a biotechnology R&D and product company whose mission is to create and develop highly innovative diagnostic reagents and assays for infectious diseases and bio-terrorism threat agents. We focus on veterinary, domestic preparedness, clinical, antibody and ELISA products.Nabi is developing breakthrough anti-infective products, vaccines and specific polyclonal antibodies to address life-threatening bacterial and viral diseases and their associated complications.EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMedâ s drug candidates target disease cells and the blood vessels that nourish them. The companyâ s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammationâ processes that are vital to the progression of cancer and other diseases. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.�� �� ��

BIOQUAL has commercial and government contracts providing holding and technical services using animal models ranging from mice to non-human primates. Applications include breeding, immunological and/or disease applications.Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple missionâ��to protect life. The company develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the bodyâ��s immune system to prevent or treat disease. The companyâ��s biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThraxà ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The companyâ��s commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.�

SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With over 1,300 employees and 2,000 trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries. SGS' state of the art facilities include: three Phase I units with a total of 162 beds, four bioanalytical labs, and Phase II-IV clinical trial management offices across Europe, North America & Asia. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can significantly improve client's drug development timelines and decision-making processes.Quality Biological manufacturers and sells biological reagents and cell culture media. They also provide facilities management and contract support to government and private institutions.Funtional Genetics Inc. is a growing biotechnology comapny which is a privately held firm focused on developing level novel drugs for infectious diseases including: Influenza, HIV, Ebola, and Hemorrhagic fever.Appropriate Technical Resources, Inc. has been serving the scientific research community for over 25 years in sales, service, and manufacturing. ATR currently manufactures the hybridization ovens for Affymetrix as well as small accessory products for research. ATR is the US distributor for Infors AG in Switzerland and manufactures the unique stackable cabinet shakers for growth of bacteria, yeast, insect cells, and mammalian cells. ATR promotes the Infors line of fermenters in the US. ATR Biotech, our CA company is located in Fremont and supports customers with sales and service.Sensors for Medicine and Science provides sensing technologies for the detection and measurement of molecules of significant commercial interest. The Company's lead product development effort is a tiny implantable glucose sensor for diabetics.

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.Cato Research is an independent, full-service contract research and development organization with international resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics, and medical devices to market.Bioscience International, Inc. provides microbiologists with microbial air samplers, automated medium preparation equipment, autoclaves, environmental monitoring tools and NIST traceable calibration services.

Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for use on wounds and other applications. The current offering is the AutoloGel(tm) System, a process that utilizes an autologous platelet gel composed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.

Calibrant Biosystems is pioneering the discovery of novel proteins targets and biomarkers for the treatment of cancer. Calibrant's uniquely targeted approach to biomarker discovery is based on a proprietary technology platform (Gemini) which enables rapid, comprehensive, and quantitative protein profiling from limited microdissected tissue specimens. The company engages in discovery and developmen partnerships with pharmaceutical and biotechnology companies, and outlicensing of novel drug targets and diagnostic markers developed through discovery partnerships with leading clinical researchers.

BIOCON, Inc. is a research laboratory servicing the biomedical and biotechnology communities and specializing in animal related services and equipped to provide all phases of animal research, transgen breeding, and custom antibody production.ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005Discover and validate novel drug-discovery targets, with particular emphasis on GPCR targets. Also supplies a variety of products and services (such as large-scale cell culture and large-scale transfections) to the drug discovery community.

The EMMES Corporation is a contract research organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical support for clinical research, including standard operating procedure (SOP) and protocol development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the culmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease processes and potential therapies.Headquartered in Rockville, Maryland, THX is a start-up life science Company with a singular focus: enabling the promise of personalized therapy to become a reality. Theranostics is the ability to use a diagnostic biomarker(s) for selecting and tailoring therapy. THX is focusing on oncology, diabetes, inflammation, obesity, cardiovascular disease and infectious disease indications.BioFactura is committed to bringing innovative science, advanced process technology, and total quality services to the pioneers of biologic medicine. We offer a broad range of process development and manufacturing services to customers and partners seeking to bring promising therapeutics, vaccines, and diagnostics to the commercial markets. In addition, BioFactura is utilizing its extensive experience to develop technologies that will add value to biopharmaceuticals as they move from discovery through the clinic and into the marketplace.Lab Products is the leading manufacturer of quality products for the biomedical research community. Products include an extensive line of equipment for the housing of laboratory animals as well as a variety of environmental control systems.AscentGene, Inc. is a developing stage biotechnology company that uses its proprietary innovative technologies to develop, manufacture, and market a new generation of diagnostic devices, novel drugs for human diseases and other bio-products for research, drug development, and other medical applications. AscentGene is affiliated with the Technology Advanced Program (TAP) at the University of Maryland at College Park.

Bacilligen is an NIH-funded Maryland corporation whose primary focus is the development of vaccine platform technologies for AIDS and biodefense/emergency preparedness. The company is also pursuing development of a next generation protein manufacturing technology with specific advantages in emergency preparedness. Finally, we are also pursuing a treatment for bladder cancer.Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.Doe & Ingalls of Maryland is a chemical service provider who helps biotechnology and electronic companies build reliable chemical supply chains that meet their compliance, risk and operational goals. We supply brand name chemicals from a worldwide network of quality manufacturers and complement these products with in-house services such as specialty sourcing, lot control, onsite sampling, temperature-controlled storage, chemical management and risk mitigation planning. The company has four locations on the east coast, including Jessup, Maryland; Richmond, Virginia; Durham, North Carolina; and Tampa, Florida. Our service centers are GMP-compliant and operate under proven ISO 9001: 2000 procedures.

Creatv MicroTech develops diagnostic instruments, devices and research tools in the following categories: · Ultra-sensitive fluorometer/luminometer platforms for testing of proteins, bacteria, viruses, cells, DNA, etc. · Immunoassays combined with PCR to detect pathogens in food, water and the environment such as E. coli, Salmonella, anthrax spores, etc. · Antimortem test for Prion Disease · Diagnostic test for aggressive versus indolent chronic lymphocytic leukemia (CLL) · Immunoassay combined with enzymatic assay to detect botulinum toxin. · High-aspect-ratio microfabrication of metal and composites. Applications include x-ray anti-scatter grids, nuclear collimators, high-density cell culture plates, etc.Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery, drug response monitoring, bio-security and other applications has been published in 12 peer-reviewed journals.20/20 GeneSystems, Inc. is a biotechnology company that has developed and is now selling an innovative proteomics product line that provides drug companies and life scientists with a digital "snapshot" of the protein signaling pathways in disease samples. The proteomic snapshot allows drug therapies to be disigned and ultimately personalized to patients based on the protein profiles of the diseases.Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

With 2006 net sales of 28.4 billion euros and an estimated 100,000 employees worldwide, sanofi-aventis is one of the world's largest pharmaceutical companies. Global headquarters are located in Paris, France and U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis U.S. employs approximately 16,000 employees, with 8,000 sales professionals. The U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis' R&D organization is comprised of approximately 17,500 scientists working in over 28 research centers around the world. Sanofi-aventis' current portfolio includes over 50 compounds. Sanofi-aventis has 7 major therapeutic areas: Cardiology, Thrombosis, Oncology, Internal Medicine, Metabolic disorders, diseases of the Central Nervous System and Vaccines.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

KamTek promotes investigations in systems biology by offering Genomics, Proteomics and Glycomics solutions in the form of: (1) Microarray Bio-Chip Services such as Microarray Printing, High Throughput Immunological or Gene Expression Assays and other Molecular Biology Services; (2) Cell Culture; and (3) Bio-Repository Services.

Advance Genomics is a biotechnology company organized in 2007 to address the research and validation needs in the human and animal biotech industry. The company uses the Illumina microarray platform to provide SNP genotyping, LOH and CNV studies, and gene expression analyses as well as experimental design consultation and data analysis services. Our scientists are experienced in developing custom molecular assays for clients using either microarray or multiplex PCR configurations. The company also provides genetic characterization and pathogen testing services of tissue samples and cell lines. The laboratory is located in Fairfax, Virginia just outside Washington, DC.

Alba Therapeutics Corporation is a clinical stage biopharmaceutical company focused on the discovery, development, production and marketing of pharmaceuticals for the treatment of inflammatory and immune-related diseases.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.Arcion Therapeutics Inc. is a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain. Arcion has a pipeline of products being developed for the treatment of painful diabetic neuropathy, post-herpetic neuralgia and other forms of moderate and severe pain. The company is located in Baltimore, Maryland.BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

Housed in the Jerome H. Holland Laboratory for the Biomedical Sciences in Rockville, Maryland, the Red Cross biomedical R&D program investigates transfusion-transmissible infections and facilitates improvements in blood collection, processing, and provision. The program's researchers include internationally respected experts in transfusion technology, transfusion-transmitted diseases, and blood component biology.

VIRxSYS Corporation is an early-stage biotechnology company developing products based on novel gene therapy platforms under the SmartVector (TM) trade name. Potential products include therapeutic treatments and vaccines for a variety of diseases

STB Lifesaving Technologies, Inc. was founded to support the research, development, and commercialization of enhanced hemostatic technologies, encompassing a broad range of products with the ability to control bleeding. STB, Inc. is currently focused on the development and commercialization of novel FAST dressing products designed to arrest severe hemorrhages. The widespread medical applications of the Company's dressing products will dramatically reduce fatalities caused by blood loss resulting from trauma, surgery or pathologic conditions.

WMP's staff previously started two companies in molecular breast imaging. We are now engaged in cooperative projects with local and international academic groups, focused on high resolution MRI and molecular imaging.

Global Research Services (GRS) is a full-service clinical trials management organization with a specialized focus on the development of cardiovascular and metabolic drugs and devices. The staff of GRS has been serving the sponsors of Phase I-IV research for over 20 years. Headquartered in Rockville, Maryland, GRS is a founding member of the Association of Clinical Research Organization (ACRO) and operates additional offices in Canada, China, Germany and Poland.

DP Clinical (DPC) is a full service contract research organization (CRO) located in the heart of the I-270 Technology Corridor in Rockville, Maryland. Since 1994 DPC, a minority-owned business, has been serving pharmaceutical, biotechnology and medical device clients and providing clients with project management, monitoring, data management, data analysis, quality assurance and regulatory for Phase I – IV clinical trials. DPC has built a strong reputation for high standards of quality, data integrity, cost-effectiveness and client satisfaction.

Clarassance is a privately held Delaware Corporation formed exclusively to develop novel biopharmaceutical candidates derived from the secretoglobin family of proteins, initially targeting inflammatory and immune diseases. More specifically, the company will advance the clinical development of its lead candidate, called Claragen, in respiratory disease. The company will take Claragen through Phase 2a and 2b clinical trials to demonstrate efficacy in patients with chronic nasal rhinitis, sinusitis, and nasal polyposis, a significant value-driving milestone. The company will operate in virtual mode, utilizing consultants and contract research organizations as needed, and maintaining a small staff and office in Rockville, MD, through completion of this milestone.

CytImmune is focused on developing colloidal gold as a targeted drug/gene delivery system. The safe, effective delivery of TNF bound to colloidal gold for cancer treatment demonstrates the utility of this delivery system.

The Foundation for the National Institutes of Health supports the mission of the Natioanl Institutes of Health, the premier research organization in the world and the steward of our nation's investment in medical discovery. The Foundation for NIH creates public-private partnerships to seek solutions for cancer, heart disease, Alzheimer's, diabetes, depresstion and other illnesses, as well as help to develop, improve and deliver life-saving vaccines.

The Center for Advanced Research in Biotechnology (CARB) is a research center of the University of Maryland Biotechnology Institute (UMBI). CARB is staffed by collaborating scientists from UMBI, the National Institute of Standards and Technology (NIST) and UMBI's Center for Biosystems Research (CBR) with aim of integrating information from molecular and biological research on complex biological systems. Our facilities are located on the recently expanded (UMBI) Shady Grove campus of the University System of Maryland.

Panacea Pharmaceuticls, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The company's product development strategy is based on novel therapeutic agents and approaches for cancer diagnosis and treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies.

Neuralstem is a biotechnology company focused on developing and commercializing human neural stem cell technology in the field of regenerative medicine. Co. focuses primarily on the field of Cell Therapy, which involves the development and commercialization of treatments based on transplanting human neural stem cells.

QRxPharma is a late-stage specialty pharmaceutical company with repositioned drugs in clinical development for the treatment of pain and neurodegenerative diseases. The Company is listed on the Australian Securities Exchange (ASX) as "QRX", and is headquartered in Sydney, Australia. Clinical trials are being conducted in the US, with offices in Rockville, MD.

RAPID Laboratories, Inc. is a drug discovery and development company whose purpose is the development of small receptor active peptides for the treatment of HIV/AIDS, development of an HIV vaccine, and the creation of novel anti-inflammatory peptides useful in the treatment of chronic inflammatory and degenerative diseases for which few or no effective treatments exist.

Protein Potential provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids for research and development. Protein Potential also provides production clone generation; fermentation optimization and process development; development of analytical assays; development of bulk and drug product lot release assays; including potency, immunogenicity and antigenicity; studies of the immunogenicity of vaccine candidates; documentation; and the technologicial know-how to transition therapeutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.

ProCell Corporation, was founded in 2000 to develop and commercialize discoveries made for the pre- and post-exposure treatment for nerve agent exposure and the treatment, diagnosis, and control of global infectious diseases of which HIV is the initial target.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

Keygene develops and applies novel technologies in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design.

KAI's staff of over 70 full time employees includes senior project managers, physicians, Ph.D. researchers, clinical research associates (CRAs), information technology experts, database and web designers, statistical programmers, data managers, pharmacologists, and research assistants.

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

SAIC provides technical and analytical contract support for biomedical product development. Their operations contain biomedical scientists, chemists, biomedical engineers, cost analysts, data base developers, and graphic, publications, and meeting support staff. Business focus is support to biomedical product development, specially FDA regulatory affairs regulatory submittals and Good Manufacturing Practices.

GeneDx provides rapid molecular diagnosis of rare hereditary disorders, serving the clinical needs of patients, physicians genetic counselors and researchers worldwide. We offer mutation detection, genotyping, carrier detection and prenatal diagnosis in over 130 diseases. GeneDx specializes in translating new genetic tests from the research laboratory to the medical community.

Tetracore is a biotechnology R&D and product company whose mission is to create and develop highly innovative diagnostic reagents and assays for infectious diseases and bio-terrorism threat agents. We focus on veterinary, domestic preparedness, clinical, antibody and ELISA products.

EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMedâ s drug candidates target disease cells and the blood vessels that nourish them. The companyâ s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammationâ processes that are vital to the progression of cancer and other diseases. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.�� �� ��

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple missionâ��to protect life. The company develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the bodyâ��s immune system to prevent or treat disease. The companyâ��s biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThraxà ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The companyâ��s commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.�

SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With over 1,300 employees and 2,000 trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries. SGS' state of the art facilities include: three Phase I units with a total of 162 beds, four bioanalytical labs, and Phase II-IV clinical trial management offices across Europe, North America & Asia. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can significantly improve client's drug development timelines and decision-making processes.

Appropriate Technical Resources, Inc. has been serving the scientific research community for over 25 years in sales, service, and manufacturing. ATR currently manufactures the hybridization ovens for Affymetrix as well as small accessory products for research. ATR is the US distributor for Infors AG in Switzerland and manufactures the unique stackable cabinet shakers for growth of bacteria, yeast, insect cells, and mammalian cells. ATR promotes the Infors line of fermenters in the US. ATR Biotech, our CA company is located in Fremont and supports customers with sales and service.

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.Cato Research is an independent, full-service contract research and development organization with international resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics, and medical devices to market.

Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for use on wounds and other applications. The current offering is the AutoloGel(tm) System, a process that utilizes an autologous platelet gel composed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.

Calibrant Biosystems is pioneering the discovery of novel proteins targets and biomarkers for the treatment of cancer. Calibrant's uniquely targeted approach to biomarker discovery is based on a proprietary technology platform (Gemini) which enables rapid, comprehensive, and quantitative protein profiling from limited microdissected tissue specimens. The company engages in discovery and developmen partnerships with pharmaceutical and biotechnology companies, and outlicensing of novel drug targets and diagnostic markers developed through discovery partnerships with leading clinical researchers.

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

The EMMES Corporation is a contract research organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical support for clinical research, including standard operating procedure (SOP) and protocol development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the culmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease processes and potential therapies.Headquartered in Rockville, Maryland, THX is a start-up life science Company with a singular focus: enabling the promise of personalized therapy to become a reality. Theranostics is the ability to use a diagnostic biomarker(s) for selecting and tailoring therapy. THX is focusing on oncology, diabetes, inflammation, obesity, cardiovascular disease and infectious disease indications.BioFactura is committed to bringing innovative science, advanced process technology, and total quality services to the pioneers of biologic medicine. We offer a broad range of process development and manufacturing services to customers and partners seeking to bring promising therapeutics, vaccines, and diagnostics to the commercial markets. In addition, BioFactura is utilizing its extensive experience to develop technologies that will add value to biopharmaceuticals as they move from discovery through the clinic and into the marketplace.

AscentGene, Inc. is a developing stage biotechnology company that uses its proprietary innovative technologies to develop, manufacture, and market a new generation of diagnostic devices, novel drugs for human diseases and other bio-products for research, drug development, and other medical applications. AscentGene is affiliated with the Technology Advanced Program (TAP) at the University of Maryland at College Park.

Bacilligen is an NIH-funded Maryland corporation whose primary focus is the development of vaccine platform technologies for AIDS and biodefense/emergency preparedness. The company is also pursuing development of a next generation protein manufacturing technology with specific advantages in emergency preparedness. Finally, we are also pursuing a treatment for bladder cancer.Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.Doe & Ingalls of Maryland is a chemical service provider who helps biotechnology and electronic companies build reliable chemical supply chains that meet their compliance, risk and operational goals. We supply brand name chemicals from a worldwide network of quality manufacturers and complement these products with in-house services such as specialty sourcing, lot control, onsite sampling, temperature-controlled storage, chemical management and risk mitigation planning. The company has four locations on the east coast, including Jessup, Maryland; Richmond, Virginia; Durham, North Carolina; and Tampa, Florida. Our service centers are GMP-compliant and operate under proven ISO 9001: 2000 procedures.

Creatv MicroTech develops diagnostic instruments, devices and research tools in the following categories: · Ultra-sensitive fluorometer/luminometer platforms for testing of proteins, bacteria, viruses, cells, DNA, etc. · Immunoassays combined with PCR to detect pathogens in food, water and the environment such as E. coli, Salmonella, anthrax spores, etc. · Antimortem test for Prion Disease · Diagnostic test for aggressive versus indolent chronic lymphocytic leukemia (CLL) · Immunoassay combined with enzymatic assay to detect botulinum toxin. · High-aspect-ratio microfabrication of metal and composites. Applications include x-ray anti-scatter grids, nuclear collimators, high-density cell culture plates, etc.Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery, drug response monitoring, bio-security and other applications has been published in 12 peer-reviewed journals.20/20 GeneSystems, Inc. is a biotechnology company that has developed and is now selling an innovative proteomics product line that provides drug companies and life scientists with a digital "snapshot" of the protein signaling pathways in disease samples. The proteomic snapshot allows drug therapies to be disigned and ultimately personalized to patients based on the protein profiles of the diseases.Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

With 2006 net sales of 28.4 billion euros and an estimated 100,000 employees worldwide, sanofi-aventis is one of the world's largest pharmaceutical companies. Global headquarters are located in Paris, France and U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis U.S. employs approximately 16,000 employees, with 8,000 sales professionals. The U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis' R&D organization is comprised of approximately 17,500 scientists working in over 28 research centers around the world. Sanofi-aventis' current portfolio includes over 50 compounds. Sanofi-aventis has 7 major therapeutic areas: Cardiology, Thrombosis, Oncology, Internal Medicine, Metabolic disorders, diseases of the Central Nervous System and Vaccines.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

KamTek promotes investigations in systems biology by offering Genomics, Proteomics and Glycomics solutions in the form of: (1) Microarray Bio-Chip Services such as Microarray Printing, High Throughput Immunological or Gene Expression Assays and other Molecular Biology Services; (2) Cell Culture; and (3) Bio-Repository Services.

Advance Genomics is a biotechnology company organized in 2007 to address the research and validation needs in the human and animal biotech industry. The company uses the Illumina microarray platform to provide SNP genotyping, LOH and CNV studies, and gene expression analyses as well as experimental design consultation and data analysis services. Our scientists are experienced in developing custom molecular assays for clients using either microarray or multiplex PCR configurations. The company also provides genetic characterization and pathogen testing services of tissue samples and cell lines. The laboratory is located in Fairfax, Virginia just outside Washington, DC.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.Arcion Therapeutics Inc. is a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain. Arcion has a pipeline of products being developed for the treatment of painful diabetic neuropathy, post-herpetic neuralgia and other forms of moderate and severe pain. The company is located in Baltimore, Maryland.BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

Housed in the Jerome H. Holland Laboratory for the Biomedical Sciences in Rockville, Maryland, the Red Cross biomedical R&D program investigates transfusion-transmissible infections and facilitates improvements in blood collection, processing, and provision. The program's researchers include internationally respected experts in transfusion technology, transfusion-transmitted diseases, and blood component biology.

STB Lifesaving Technologies, Inc. was founded to support the research, development, and commercialization of enhanced hemostatic technologies, encompassing a broad range of products with the ability to control bleeding. STB, Inc. is currently focused on the development and commercialization of novel FAST dressing products designed to arrest severe hemorrhages. The widespread medical applications of the Company's dressing products will dramatically reduce fatalities caused by blood loss resulting from trauma, surgery or pathologic conditions.

Global Research Services (GRS) is a full-service clinical trials management organization with a specialized focus on the development of cardiovascular and metabolic drugs and devices. The staff of GRS has been serving the sponsors of Phase I-IV research for over 20 years. Headquartered in Rockville, Maryland, GRS is a founding member of the Association of Clinical Research Organization (ACRO) and operates additional offices in Canada, China, Germany and Poland.

DP Clinical (DPC) is a full service contract research organization (CRO) located in the heart of the I-270 Technology Corridor in Rockville, Maryland. Since 1994 DPC, a minority-owned business, has been serving pharmaceutical, biotechnology and medical device clients and providing clients with project management, monitoring, data management, data analysis, quality assurance and regulatory for Phase I – IV clinical trials. DPC has built a strong reputation for high standards of quality, data integrity, cost-effectiveness and client satisfaction.

Clarassance is a privately held Delaware Corporation formed exclusively to develop novel biopharmaceutical candidates derived from the secretoglobin family of proteins, initially targeting inflammatory and immune diseases. More specifically, the company will advance the clinical development of its lead candidate, called Claragen, in respiratory disease. The company will take Claragen through Phase 2a and 2b clinical trials to demonstrate efficacy in patients with chronic nasal rhinitis, sinusitis, and nasal polyposis, a significant value-driving milestone. The company will operate in virtual mode, utilizing consultants and contract research organizations as needed, and maintaining a small staff and office in Rockville, MD, through completion of this milestone.

The Foundation for the National Institutes of Health supports the mission of the Natioanl Institutes of Health, the premier research organization in the world and the steward of our nation's investment in medical discovery. The Foundation for NIH creates public-private partnerships to seek solutions for cancer, heart disease, Alzheimer's, diabetes, depresstion and other illnesses, as well as help to develop, improve and deliver life-saving vaccines.

The Center for Advanced Research in Biotechnology (CARB) is a research center of the University of Maryland Biotechnology Institute (UMBI). CARB is staffed by collaborating scientists from UMBI, the National Institute of Standards and Technology (NIST) and UMBI's Center for Biosystems Research (CBR) with aim of integrating information from molecular and biological research on complex biological systems. Our facilities are located on the recently expanded (UMBI) Shady Grove campus of the University System of Maryland.

Panacea Pharmaceuticls, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The company's product development strategy is based on novel therapeutic agents and approaches for cancer diagnosis and treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies.

Neuralstem is a biotechnology company focused on developing and commercializing human neural stem cell technology in the field of regenerative medicine. Co. focuses primarily on the field of Cell Therapy, which involves the development and commercialization of treatments based on transplanting human neural stem cells.

QRxPharma is a late-stage specialty pharmaceutical company with repositioned drugs in clinical development for the treatment of pain and neurodegenerative diseases. The Company is listed on the Australian Securities Exchange (ASX) as "QRX", and is headquartered in Sydney, Australia. Clinical trials are being conducted in the US, with offices in Rockville, MD.

RAPID Laboratories, Inc. is a drug discovery and development company whose purpose is the development of small receptor active peptides for the treatment of HIV/AIDS, development of an HIV vaccine, and the creation of novel anti-inflammatory peptides useful in the treatment of chronic inflammatory and degenerative diseases for which few or no effective treatments exist.

Protein Potential provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids for research and development. Protein Potential also provides production clone generation; fermentation optimization and process development; development of analytical assays; development of bulk and drug product lot release assays; including potency, immunogenicity and antigenicity; studies of the immunogenicity of vaccine candidates; documentation; and the technologicial know-how to transition therapeutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

Keygene develops and applies novel technologies in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design.

KAI's staff of over 70 full time employees includes senior project managers, physicians, Ph.D. researchers, clinical research associates (CRAs), information technology experts, database and web designers, statistical programmers, data managers, pharmacologists, and research assistants.

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

SAIC provides technical and analytical contract support for biomedical product development. Their operations contain biomedical scientists, chemists, biomedical engineers, cost analysts, data base developers, and graphic, publications, and meeting support staff. Business focus is support to biomedical product development, specially FDA regulatory affairs regulatory submittals and Good Manufacturing Practices.

GeneDx provides rapid molecular diagnosis of rare hereditary disorders, serving the clinical needs of patients, physicians genetic counselors and researchers worldwide. We offer mutation detection, genotyping, carrier detection and prenatal diagnosis in over 130 diseases. GeneDx specializes in translating new genetic tests from the research laboratory to the medical community.

EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMedâ s drug candidates target disease cells and the blood vessels that nourish them. The companyâ s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammationâ processes that are vital to the progression of cancer and other diseases. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.�� �� ��

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple missionâ��to protect life. The company develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the bodyâ��s immune system to prevent or treat disease. The companyâ��s biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThraxà ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The companyâ��s commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.�

SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With over 1,300 employees and 2,000 trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries. SGS' state of the art facilities include: three Phase I units with a total of 162 beds, four bioanalytical labs, and Phase II-IV clinical trial management offices across Europe, North America & Asia. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can significantly improve client's drug development timelines and decision-making processes.

Appropriate Technical Resources, Inc. has been serving the scientific research community for over 25 years in sales, service, and manufacturing. ATR currently manufactures the hybridization ovens for Affymetrix as well as small accessory products for research. ATR is the US distributor for Infors AG in Switzerland and manufactures the unique stackable cabinet shakers for growth of bacteria, yeast, insect cells, and mammalian cells. ATR promotes the Infors line of fermenters in the US. ATR Biotech, our CA company is located in Fremont and supports customers with sales and service.

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates for use on wounds and other applications. The current offering is the AutoloGel(tm) System, a process that utilizes an autologous platelet gel composed of multiple growth factors, other platelet releasates, and fibrin matrix. Additional information regarding Cytomedix is available at: http://www.cytomedix.com.

Calibrant Biosystems is pioneering the discovery of novel proteins targets and biomarkers for the treatment of cancer. Calibrant's uniquely targeted approach to biomarker discovery is based on a proprietary technology platform (Gemini) which enables rapid, comprehensive, and quantitative protein profiling from limited microdissected tissue specimens. The company engages in discovery and developmen partnerships with pharmaceutical and biotechnology companies, and outlicensing of novel drug targets and diagnostic markers developed through discovery partnerships with leading clinical researchers.

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

The EMMES Corporation is a contract research organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical support for clinical research, including standard operating procedure (SOP) and protocol development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the culmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease processes and potential therapies.Headquartered in Rockville, Maryland, THX is a start-up life science Company with a singular focus: enabling the promise of personalized therapy to become a reality. Theranostics is the ability to use a diagnostic biomarker(s) for selecting and tailoring therapy. THX is focusing on oncology, diabetes, inflammation, obesity, cardiovascular disease and infectious disease indications.BioFactura is committed to bringing innovative science, advanced process technology, and total quality services to the pioneers of biologic medicine. We offer a broad range of process development and manufacturing services to customers and partners seeking to bring promising therapeutics, vaccines, and diagnostics to the commercial markets. In addition, BioFactura is utilizing its extensive experience to develop technologies that will add value to biopharmaceuticals as they move from discovery through the clinic and into the marketplace.

AscentGene, Inc. is a developing stage biotechnology company that uses its proprietary innovative technologies to develop, manufacture, and market a new generation of diagnostic devices, novel drugs for human diseases and other bio-products for research, drug development, and other medical applications. AscentGene is affiliated with the Technology Advanced Program (TAP) at the University of Maryland at College Park.

Bacilligen is an NIH-funded Maryland corporation whose primary focus is the development of vaccine platform technologies for AIDS and biodefense/emergency preparedness. The company is also pursuing development of a next generation protein manufacturing technology with specific advantages in emergency preparedness. Finally, we are also pursuing a treatment for bladder cancer.Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.Doe & Ingalls of Maryland is a chemical service provider who helps biotechnology and electronic companies build reliable chemical supply chains that meet their compliance, risk and operational goals. We supply brand name chemicals from a worldwide network of quality manufacturers and complement these products with in-house services such as specialty sourcing, lot control, onsite sampling, temperature-controlled storage, chemical management and risk mitigation planning. The company has four locations on the east coast, including Jessup, Maryland; Richmond, Virginia; Durham, North Carolina; and Tampa, Florida. Our service centers are GMP-compliant and operate under proven ISO 9001: 2000 procedures.

Creatv MicroTech develops diagnostic instruments, devices and research tools in the following categories: · Ultra-sensitive fluorometer/luminometer platforms for testing of proteins, bacteria, viruses, cells, DNA, etc. · Immunoassays combined with PCR to detect pathogens in food, water and the environment such as E. coli, Salmonella, anthrax spores, etc. · Antimortem test for Prion Disease · Diagnostic test for aggressive versus indolent chronic lymphocytic leukemia (CLL) · Immunoassay combined with enzymatic assay to detect botulinum toxin. · High-aspect-ratio microfabrication of metal and composites. Applications include x-ray anti-scatter grids, nuclear collimators, high-density cell culture plates, etc.Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery, drug response monitoring, bio-security and other applications has been published in 12 peer-reviewed journals.20/20 GeneSystems, Inc. is a biotechnology company that has developed and is now selling an innovative proteomics product line that provides drug companies and life scientists with a digital "snapshot" of the protein signaling pathways in disease samples. The proteomic snapshot allows drug therapies to be disigned and ultimately personalized to patients based on the protein profiles of the diseases.Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

With 2006 net sales of 28.4 billion euros and an estimated 100,000 employees worldwide, sanofi-aventis is one of the world's largest pharmaceutical companies. Global headquarters are located in Paris, France and U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis U.S. employs approximately 16,000 employees, with 8,000 sales professionals. The U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis' R&D organization is comprised of approximately 17,500 scientists working in over 28 research centers around the world. Sanofi-aventis' current portfolio includes over 50 compounds. Sanofi-aventis has 7 major therapeutic areas: Cardiology, Thrombosis, Oncology, Internal Medicine, Metabolic disorders, diseases of the Central Nervous System and Vaccines.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

Advance Genomics is a biotechnology company organized in 2007 to address the research and validation needs in the human and animal biotech industry. The company uses the Illumina microarray platform to provide SNP genotyping, LOH and CNV studies, and gene expression analyses as well as experimental design consultation and data analysis services. Our scientists are experienced in developing custom molecular assays for clients using either microarray or multiplex PCR configurations. The company also provides genetic characterization and pathogen testing services of tissue samples and cell lines. The laboratory is located in Fairfax, Virginia just outside Washington, DC.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.

BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

Housed in the Jerome H. Holland Laboratory for the Biomedical Sciences in Rockville, Maryland, the Red Cross biomedical R&D program investigates transfusion-transmissible infections and facilitates improvements in blood collection, processing, and provision. The program's researchers include internationally respected experts in transfusion technology, transfusion-transmitted diseases, and blood component biology.

STB Lifesaving Technologies, Inc. was founded to support the research, development, and commercialization of enhanced hemostatic technologies, encompassing a broad range of products with the ability to control bleeding. STB, Inc. is currently focused on the development and commercialization of novel FAST dressing products designed to arrest severe hemorrhages. The widespread medical applications of the Company's dressing products will dramatically reduce fatalities caused by blood loss resulting from trauma, surgery or pathologic conditions.

Global Research Services (GRS) is a full-service clinical trials management organization with a specialized focus on the development of cardiovascular and metabolic drugs and devices. The staff of GRS has been serving the sponsors of Phase I-IV research for over 20 years. Headquartered in Rockville, Maryland, GRS is a founding member of the Association of Clinical Research Organization (ACRO) and operates additional offices in Canada, China, Germany and Poland.

DP Clinical (DPC) is a full service contract research organization (CRO) located in the heart of the I-270 Technology Corridor in Rockville, Maryland. Since 1994 DPC, a minority-owned business, has been serving pharmaceutical, biotechnology and medical device clients and providing clients with project management, monitoring, data management, data analysis, quality assurance and regulatory for Phase I – IV clinical trials. DPC has built a strong reputation for high standards of quality, data integrity, cost-effectiveness and client satisfaction.

Clarassance is a privately held Delaware Corporation formed exclusively to develop novel biopharmaceutical candidates derived from the secretoglobin family of proteins, initially targeting inflammatory and immune diseases. More specifically, the company will advance the clinical development of its lead candidate, called Claragen, in respiratory disease. The company will take Claragen through Phase 2a and 2b clinical trials to demonstrate efficacy in patients with chronic nasal rhinitis, sinusitis, and nasal polyposis, a significant value-driving milestone. The company will operate in virtual mode, utilizing consultants and contract research organizations as needed, and maintaining a small staff and office in Rockville, MD, through completion of this milestone.

The Foundation for the National Institutes of Health supports the mission of the Natioanl Institutes of Health, the premier research organization in the world and the steward of our nation's investment in medical discovery. The Foundation for NIH creates public-private partnerships to seek solutions for cancer, heart disease, Alzheimer's, diabetes, depresstion and other illnesses, as well as help to develop, improve and deliver life-saving vaccines.

The Center for Advanced Research in Biotechnology (CARB) is a research center of the University of Maryland Biotechnology Institute (UMBI). CARB is staffed by collaborating scientists from UMBI, the National Institute of Standards and Technology (NIST) and UMBI's Center for Biosystems Research (CBR) with aim of integrating information from molecular and biological research on complex biological systems. Our facilities are located on the recently expanded (UMBI) Shady Grove campus of the University System of Maryland.

Panacea Pharmaceuticls, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The company's product development strategy is based on novel therapeutic agents and approaches for cancer diagnosis and treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies.

RAPID Laboratories, Inc. is a drug discovery and development company whose purpose is the development of small receptor active peptides for the treatment of HIV/AIDS, development of an HIV vaccine, and the creation of novel anti-inflammatory peptides useful in the treatment of chronic inflammatory and degenerative diseases for which few or no effective treatments exist.

Protein Potential provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids for research and development. Protein Potential also provides production clone generation; fermentation optimization and process development; development of analytical assays; development of bulk and drug product lot release assays; including potency, immunogenicity and antigenicity; studies of the immunogenicity of vaccine candidates; documentation; and the technologicial know-how to transition therapeutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

Keygene develops and applies novel technologies in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design.

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMedâ s drug candidates target disease cells and the blood vessels that nourish them. The companyâ s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammationâ processes that are vital to the progression of cancer and other diseases. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.�� �� ��

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple missionâ��to protect life. The company develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the bodyâ��s immune system to prevent or treat disease. The companyâ��s biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThraxà ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The companyâ��s commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.�

SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With over 1,300 employees and 2,000 trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries. SGS' state of the art facilities include: three Phase I units with a total of 162 beds, four bioanalytical labs, and Phase II-IV clinical trial management offices across Europe, North America & Asia. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can significantly improve client's drug development timelines and decision-making processes.

Appropriate Technical Resources, Inc. has been serving the scientific research community for over 25 years in sales, service, and manufacturing. ATR currently manufactures the hybridization ovens for Affymetrix as well as small accessory products for research. ATR is the US distributor for Infors AG in Switzerland and manufactures the unique stackable cabinet shakers for growth of bacteria, yeast, insect cells, and mammalian cells. ATR promotes the Infors line of fermenters in the US. ATR Biotech, our CA company is located in Fremont and supports customers with sales and service.

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

Calibrant Biosystems is pioneering the discovery of novel proteins targets and biomarkers for the treatment of cancer. Calibrant's uniquely targeted approach to biomarker discovery is based on a proprietary technology platform (Gemini) which enables rapid, comprehensive, and quantitative protein profiling from limited microdissected tissue specimens. The company engages in discovery and developmen partnerships with pharmaceutical and biotechnology companies, and outlicensing of novel drug targets and diagnostic markers developed through discovery partnerships with leading clinical researchers.

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

The EMMES Corporation is a contract research organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical support for clinical research, including standard operating procedure (SOP) and protocol development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the culmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease processes and potential therapies.

BioFactura is committed to bringing innovative science, advanced process technology, and total quality services to the pioneers of biologic medicine. We offer a broad range of process development and manufacturing services to customers and partners seeking to bring promising therapeutics, vaccines, and diagnostics to the commercial markets. In addition, BioFactura is utilizing its extensive experience to develop technologies that will add value to biopharmaceuticals as they move from discovery through the clinic and into the marketplace.

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.Doe & Ingalls of Maryland is a chemical service provider who helps biotechnology and electronic companies build reliable chemical supply chains that meet their compliance, risk and operational goals. We supply brand name chemicals from a worldwide network of quality manufacturers and complement these products with in-house services such as specialty sourcing, lot control, onsite sampling, temperature-controlled storage, chemical management and risk mitigation planning. The company has four locations on the east coast, including Jessup, Maryland; Richmond, Virginia; Durham, North Carolina; and Tampa, Florida. Our service centers are GMP-compliant and operate under proven ISO 9001: 2000 procedures.

Creatv MicroTech develops diagnostic instruments, devices and research tools in the following categories: · Ultra-sensitive fluorometer/luminometer platforms for testing of proteins, bacteria, viruses, cells, DNA, etc. · Immunoassays combined with PCR to detect pathogens in food, water and the environment such as E. coli, Salmonella, anthrax spores, etc. · Antimortem test for Prion Disease · Diagnostic test for aggressive versus indolent chronic lymphocytic leukemia (CLL) · Immunoassay combined with enzymatic assay to detect botulinum toxin. · High-aspect-ratio microfabrication of metal and composites. Applications include x-ray anti-scatter grids, nuclear collimators, high-density cell culture plates, etc.Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery, drug response monitoring, bio-security and other applications has been published in 12 peer-reviewed journals.

Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

With 2006 net sales of 28.4 billion euros and an estimated 100,000 employees worldwide, sanofi-aventis is one of the world's largest pharmaceutical companies. Global headquarters are located in Paris, France and U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis U.S. employs approximately 16,000 employees, with 8,000 sales professionals. The U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis' R&D organization is comprised of approximately 17,500 scientists working in over 28 research centers around the world. Sanofi-aventis' current portfolio includes over 50 compounds. Sanofi-aventis has 7 major therapeutic areas: Cardiology, Thrombosis, Oncology, Internal Medicine, Metabolic disorders, diseases of the Central Nervous System and Vaccines.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

Advance Genomics is a biotechnology company organized in 2007 to address the research and validation needs in the human and animal biotech industry. The company uses the Illumina microarray platform to provide SNP genotyping, LOH and CNV studies, and gene expression analyses as well as experimental design consultation and data analysis services. Our scientists are experienced in developing custom molecular assays for clients using either microarray or multiplex PCR configurations. The company also provides genetic characterization and pathogen testing services of tissue samples and cell lines. The laboratory is located in Fairfax, Virginia just outside Washington, DC.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.

BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

STB Lifesaving Technologies, Inc. was founded to support the research, development, and commercialization of enhanced hemostatic technologies, encompassing a broad range of products with the ability to control bleeding. STB, Inc. is currently focused on the development and commercialization of novel FAST dressing products designed to arrest severe hemorrhages. The widespread medical applications of the Company's dressing products will dramatically reduce fatalities caused by blood loss resulting from trauma, surgery or pathologic conditions.

Global Research Services (GRS) is a full-service clinical trials management organization with a specialized focus on the development of cardiovascular and metabolic drugs and devices. The staff of GRS has been serving the sponsors of Phase I-IV research for over 20 years. Headquartered in Rockville, Maryland, GRS is a founding member of the Association of Clinical Research Organization (ACRO) and operates additional offices in Canada, China, Germany and Poland.

DP Clinical (DPC) is a full service contract research organization (CRO) located in the heart of the I-270 Technology Corridor in Rockville, Maryland. Since 1994 DPC, a minority-owned business, has been serving pharmaceutical, biotechnology and medical device clients and providing clients with project management, monitoring, data management, data analysis, quality assurance and regulatory for Phase I – IV clinical trials. DPC has built a strong reputation for high standards of quality, data integrity, cost-effectiveness and client satisfaction.

Clarassance is a privately held Delaware Corporation formed exclusively to develop novel biopharmaceutical candidates derived from the secretoglobin family of proteins, initially targeting inflammatory and immune diseases. More specifically, the company will advance the clinical development of its lead candidate, called Claragen, in respiratory disease. The company will take Claragen through Phase 2a and 2b clinical trials to demonstrate efficacy in patients with chronic nasal rhinitis, sinusitis, and nasal polyposis, a significant value-driving milestone. The company will operate in virtual mode, utilizing consultants and contract research organizations as needed, and maintaining a small staff and office in Rockville, MD, through completion of this milestone.

The Center for Advanced Research in Biotechnology (CARB) is a research center of the University of Maryland Biotechnology Institute (UMBI). CARB is staffed by collaborating scientists from UMBI, the National Institute of Standards and Technology (NIST) and UMBI's Center for Biosystems Research (CBR) with aim of integrating information from molecular and biological research on complex biological systems. Our facilities are located on the recently expanded (UMBI) Shady Grove campus of the University System of Maryland.

Panacea Pharmaceuticls, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The company's product development strategy is based on novel therapeutic agents and approaches for cancer diagnosis and treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies.

Protein Potential provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids for research and development. Protein Potential also provides production clone generation; fermentation optimization and process development; development of analytical assays; development of bulk and drug product lot release assays; including potency, immunogenicity and antigenicity; studies of the immunogenicity of vaccine candidates; documentation; and the technologicial know-how to transition therapeutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

Keygene develops and applies novel technologies in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design.

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMedâ s drug candidates target disease cells and the blood vessels that nourish them. The companyâ s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammationâ processes that are vital to the progression of cancer and other diseases. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.�� �� ��

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple missionâ��to protect life. The company develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the bodyâ��s immune system to prevent or treat disease. The companyâ��s biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThraxà ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The companyâ��s commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.�

SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With over 1,300 employees and 2,000 trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries. SGS' state of the art facilities include: three Phase I units with a total of 162 beds, four bioanalytical labs, and Phase II-IV clinical trial management offices across Europe, North America & Asia. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can significantly improve client's drug development timelines and decision-making processes.

Appropriate Technical Resources, Inc. has been serving the scientific research community for over 25 years in sales, service, and manufacturing. ATR currently manufactures the hybridization ovens for Affymetrix as well as small accessory products for research. ATR is the US distributor for Infors AG in Switzerland and manufactures the unique stackable cabinet shakers for growth of bacteria, yeast, insect cells, and mammalian cells. ATR promotes the Infors line of fermenters in the US. ATR Biotech, our CA company is located in Fremont and supports customers with sales and service.

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

Calibrant Biosystems is pioneering the discovery of novel proteins targets and biomarkers for the treatment of cancer. Calibrant's uniquely targeted approach to biomarker discovery is based on a proprietary technology platform (Gemini) which enables rapid, comprehensive, and quantitative protein profiling from limited microdissected tissue specimens. The company engages in discovery and developmen partnerships with pharmaceutical and biotechnology companies, and outlicensing of novel drug targets and diagnostic markers developed through discovery partnerships with leading clinical researchers.

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

The EMMES Corporation is a contract research organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical support for clinical research, including standard operating procedure (SOP) and protocol development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the culmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease processes and potential therapies.

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.Doe & Ingalls of Maryland is a chemical service provider who helps biotechnology and electronic companies build reliable chemical supply chains that meet their compliance, risk and operational goals. We supply brand name chemicals from a worldwide network of quality manufacturers and complement these products with in-house services such as specialty sourcing, lot control, onsite sampling, temperature-controlled storage, chemical management and risk mitigation planning. The company has four locations on the east coast, including Jessup, Maryland; Richmond, Virginia; Durham, North Carolina; and Tampa, Florida. Our service centers are GMP-compliant and operate under proven ISO 9001: 2000 procedures.

Creatv MicroTech develops diagnostic instruments, devices and research tools in the following categories: · Ultra-sensitive fluorometer/luminometer platforms for testing of proteins, bacteria, viruses, cells, DNA, etc. · Immunoassays combined with PCR to detect pathogens in food, water and the environment such as E. coli, Salmonella, anthrax spores, etc. · Antimortem test for Prion Disease · Diagnostic test for aggressive versus indolent chronic lymphocytic leukemia (CLL) · Immunoassay combined with enzymatic assay to detect botulinum toxin. · High-aspect-ratio microfabrication of metal and composites. Applications include x-ray anti-scatter grids, nuclear collimators, high-density cell culture plates, etc.Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery, drug response monitoring, bio-security and other applications has been published in 12 peer-reviewed journals.

Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

With 2006 net sales of 28.4 billion euros and an estimated 100,000 employees worldwide, sanofi-aventis is one of the world's largest pharmaceutical companies. Global headquarters are located in Paris, France and U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis U.S. employs approximately 16,000 employees, with 8,000 sales professionals. The U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis' R&D organization is comprised of approximately 17,500 scientists working in over 28 research centers around the world. Sanofi-aventis' current portfolio includes over 50 compounds. Sanofi-aventis has 7 major therapeutic areas: Cardiology, Thrombosis, Oncology, Internal Medicine, Metabolic disorders, diseases of the Central Nervous System and Vaccines.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

Advance Genomics is a biotechnology company organized in 2007 to address the research and validation needs in the human and animal biotech industry. The company uses the Illumina microarray platform to provide SNP genotyping, LOH and CNV studies, and gene expression analyses as well as experimental design consultation and data analysis services. Our scientists are experienced in developing custom molecular assays for clients using either microarray or multiplex PCR configurations. The company also provides genetic characterization and pathogen testing services of tissue samples and cell lines. The laboratory is located in Fairfax, Virginia just outside Washington, DC.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.

BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

Clarassance is a privately held Delaware Corporation formed exclusively to develop novel biopharmaceutical candidates derived from the secretoglobin family of proteins, initially targeting inflammatory and immune diseases. More specifically, the company will advance the clinical development of its lead candidate, called Claragen, in respiratory disease. The company will take Claragen through Phase 2a and 2b clinical trials to demonstrate efficacy in patients with chronic nasal rhinitis, sinusitis, and nasal polyposis, a significant value-driving milestone. The company will operate in virtual mode, utilizing consultants and contract research organizations as needed, and maintaining a small staff and office in Rockville, MD, through completion of this milestone.

Panacea Pharmaceuticls, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The company's product development strategy is based on novel therapeutic agents and approaches for cancer diagnosis and treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies.

Protein Potential provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids for research and development. Protein Potential also provides production clone generation; fermentation optimization and process development; development of analytical assays; development of bulk and drug product lot release assays; including potency, immunogenicity and antigenicity; studies of the immunogenicity of vaccine candidates; documentation; and the technologicial know-how to transition therapeutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

Keygene develops and applies novel technologies in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design.

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMedâ s drug candidates target disease cells and the blood vessels that nourish them. The companyâ s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammationâ processes that are vital to the progression of cancer and other diseases. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.�� �� ��

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple missionâ��to protect life. The company develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the bodyâ��s immune system to prevent or treat disease. The companyâ��s biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThraxà ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The companyâ��s commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.�

SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With over 1,300 employees and 2,000 trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries. SGS' state of the art facilities include: three Phase I units with a total of 162 beds, four bioanalytical labs, and Phase II-IV clinical trial management offices across Europe, North America & Asia. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can significantly improve client's drug development timelines and decision-making processes.

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

The EMMES Corporation is a contract research organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical support for clinical research, including standard operating procedure (SOP) and protocol development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the culmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease processes and potential therapies.

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.Doe & Ingalls of Maryland is a chemical service provider who helps biotechnology and electronic companies build reliable chemical supply chains that meet their compliance, risk and operational goals. We supply brand name chemicals from a worldwide network of quality manufacturers and complement these products with in-house services such as specialty sourcing, lot control, onsite sampling, temperature-controlled storage, chemical management and risk mitigation planning. The company has four locations on the east coast, including Jessup, Maryland; Richmond, Virginia; Durham, North Carolina; and Tampa, Florida. Our service centers are GMP-compliant and operate under proven ISO 9001: 2000 procedures.

Creatv MicroTech develops diagnostic instruments, devices and research tools in the following categories: · Ultra-sensitive fluorometer/luminometer platforms for testing of proteins, bacteria, viruses, cells, DNA, etc. · Immunoassays combined with PCR to detect pathogens in food, water and the environment such as E. coli, Salmonella, anthrax spores, etc. · Antimortem test for Prion Disease · Diagnostic test for aggressive versus indolent chronic lymphocytic leukemia (CLL) · Immunoassay combined with enzymatic assay to detect botulinum toxin. · High-aspect-ratio microfabrication of metal and composites. Applications include x-ray anti-scatter grids, nuclear collimators, high-density cell culture plates, etc.Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery, drug response monitoring, bio-security and other applications has been published in 12 peer-reviewed journals.

Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

With 2006 net sales of 28.4 billion euros and an estimated 100,000 employees worldwide, sanofi-aventis is one of the world's largest pharmaceutical companies. Global headquarters are located in Paris, France and U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis U.S. employs approximately 16,000 employees, with 8,000 sales professionals. The U.S. headquarters are in Bridgewater, NJ. Sanofi-aventis' R&D organization is comprised of approximately 17,500 scientists working in over 28 research centers around the world. Sanofi-aventis' current portfolio includes over 50 compounds. Sanofi-aventis has 7 major therapeutic areas: Cardiology, Thrombosis, Oncology, Internal Medicine, Metabolic disorders, diseases of the Central Nervous System and Vaccines.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

Advance Genomics is a biotechnology company organized in 2007 to address the research and validation needs in the human and animal biotech industry. The company uses the Illumina microarray platform to provide SNP genotyping, LOH and CNV studies, and gene expression analyses as well as experimental design consultation and data analysis services. Our scientists are experienced in developing custom molecular assays for clients using either microarray or multiplex PCR configurations. The company also provides genetic characterization and pathogen testing services of tissue samples and cell lines. The laboratory is located in Fairfax, Virginia just outside Washington, DC.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.

BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

Clarassance is a privately held Delaware Corporation formed exclusively to develop novel biopharmaceutical candidates derived from the secretoglobin family of proteins, initially targeting inflammatory and immune diseases. More specifically, the company will advance the clinical development of its lead candidate, called Claragen, in respiratory disease. The company will take Claragen through Phase 2a and 2b clinical trials to demonstrate efficacy in patients with chronic nasal rhinitis, sinusitis, and nasal polyposis, a significant value-driving milestone. The company will operate in virtual mode, utilizing consultants and contract research organizations as needed, and maintaining a small staff and office in Rockville, MD, through completion of this milestone.

Protein Potential provides pharmaceutical and biotechnology companies, and government and academic institutions with high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids for research and development. Protein Potential also provides production clone generation; fermentation optimization and process development; development of analytical assays; development of bulk and drug product lot release assays; including potency, immunogenicity and antigenicity; studies of the immunogenicity of vaccine candidates; documentation; and the technologicial know-how to transition therapeutic, vaccine, and diagnostic proteins and DNA plasmids to large scale cGMP manufacture.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

Keygene develops and applies novel technologies in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design.

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple missionâ��to protect life. The company develops, manufactures and commercializes immunobiotics, consisting of vaccines and therapeutics that assist the bodyâ��s immune system to prevent or treat disease. The companyâ��s biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Its marketed product, BioThraxà ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The companyâ��s commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs.�

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

The EMMES Corporation is a contract research organization (CRO) providing biostatistical and epidemiological project management and support, as well as organizational and logistical support for clinical research, including standard operating procedure (SOP) and protocol development. The "Advantage Suite" software family for clinical data collection and management provides our clients with a framework to rapidly define and delploy clinical trials worldwide over the Internet. Working with us represents the culmination of over 25 years of experience and expertise designing, developing and implementing projects serving commercial, government, academic, and non-profit research institutions dedicated to advancing understanding of disease processes and potential therapies.

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.

Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.

BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

Keygene develops and applies novel technologies in the field of molecular genetics for the plant breeding industry and has become an internationally recognized leader in the field of DNA marker technology. The company has built a broad technology, SNPWave, a multiplexed SNP detection system. cDNA AFLP, a robust high-throughput gene transcript profiling technology CRoPS, a high throughput SNP indentification technology that can be applied in any organism without prior sequence knowledge and a large portfolio of software applications supporting the technologies and applications. Keygene exploits its proprietary technologies, databases and know-how through comtract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design.

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.

Adlyfe, Inc. is a new biotechnology company founded in the spring of 2003 to bring innovative blood diagnostic products to the market for fatal brain diseases. These diseases are correlated to changes in proteins that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the deposition of amyloids results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms. Amyloid formation and protein build up in tissues is accociated with human diseases such as Creutzfeldt-Jakob disease (CJD), Alzheimer's, and Parkinson Disease. These debilitating diseases affect millions of people, with high mortality and significant costs of healthcare delivery. There are also important animal diseases mitigated mitigated by amyloid formation including Bovine Spongiform Encephalopathy (BSE, or Mad Cow disease), sheep scrapie, and chronic wasting disease (CWD) in deer and elk. Our inn!

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.

BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository(r), a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

Amulet Pharmaceuticals, Inc is an early stage biotechnology company developing new chemical entities for unmet medical needs serving large, rapidly growing markets. Amulet lowers development risk and improves drug safety through our proprietary NORTECH™ technology, which integrates Nitric Oxide donors into FDA approved, ommercially successful therapeutics with known safety and efficacy profiles. Our focus is on unmet needs in large markets where the pivotal signaling molecule, Nitric Oxide (NO), offers a differentiating clinical advantage that can be backed up by strong composition-of-matter claims in our intellectual property portfolio. Our initial focus is to address the unmet medical need of gastroparesis, where there is no effective treatment for up to 5 Million sufferers in the US. The goal is to complete a Phase I Clinical study by mid-2009. We plan to advance potential additional leads in Cardiovascular disease, Gastrointestinal diseases (GI), Osteoarthritis (Pain) and Ophthalmology.

BIOMERE LLC solves a critical need of biotech companies by providing access to a scientific staff, an AAALAC accredited vivarium, and proprietary animal models. Through our affordable cost structure we address the steps in the path from bench to bedside beginning with the research models through development activities and ultimately commercialization. The company offers a wide range of in-house research models but also develops customized, innovative models to address unique research requirements. BIOMERE provides guidance with government submissions, leases research space at its facility, and conducts research and development activities for clients. Internal programs at BIOMERE LLC include the development of vaccines and therapeutic agents for a range of diseases including Type 1 and Type 2 diabetes and diabetic complications including retinopathy, neuropathy and CVD. BIOMERE'S models are also widely used in studies for rheumatoid arthritis and multiple sclerosis.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

MaxCyte is a clinical-stage cell therapeutics company with rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary, non-viral, ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to commercializing successful cell-based therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addiction, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte systems has an FDA master File in place at the Center for Biologics Evaluation and Research (CBER)

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

Summit Drug Development, LLC, offers comprehensive drug development services to the biotechnology and pharmaceutical industry to advance new technologies from discovery to the marketplace. Summit is located in Rockville, Maryland, in close proximity to the Food and Drug Administration (FDA). Summit services span all areas of drug, biologics and device development including preclinical, manufacturing, regulatory, medical writing, and clinical development activities. The primary goal of Summit is to understand you r drug development needs and provide you with the levels of assistance you require to accomplish your goals and meet project milestones. Summit can assist your organization by “filling in the gaps” in managing and conducting preclinical, manufacturing, regulatory and/or clinical aspects of your development programs, thus becoming an extension of your project team. Summit staff has extensive experience in drug development in the pharma/biotech and contract service industries as well as direct experience working within the Food and Drug Administration (FDA) and the National Institute of Health (NIH). The staff has board capabilities across technology and therapeutic areas ranging from natural products and small molecules to gene therapies. With this broad experience base, Summit can provide strategic support to your organization in the preparation of comprehensive development plans as well as the resources to implement these plans.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

GenVec is an emerging biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec uses gene therapy to deliver medically beneficial proteins, such as VEGF, PEDF and TNF-alpha, directly to the site of disease. GenVec has an advanced drug discovery engine that enables the rapid discovery, testing and development of new product candidates. GenVec has an exciting product portfolio, which includes TNFeradeà ï for the treatment of cancer and BIOBYPASSà �ï¿® angiogen for the treatment of cardiovascular disease. GenVec leverages its corporate partnerships to develop product candidates, expand its technology and reduce risk. GenVec intends to become a fully integrated pharmaceutical company that will develop and commercialize products. Powered by an advanced drug discovery approach, GenVec can create new product candidates using its proprietary technologies, AdFASTà ï ¢. GenVec has an extensive intellectual property portfolio including over 380 issued, allowed or pending patents covering its product candidates and technology platforms. The Company has also established collaborations with numerous academic institutions and pharmaceutical and biotechnology companies, which are an additional source of important technology and know-how. GenVec is a publicly held company with over 85 employees, headquartered in a 43,000-square-foot research and development facility in Gaithersburg, Maryland, the hub of the metro DC biotech corridor.� � ��

ExonHit Therapeutics is the world’s leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases. ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays. “SpliceArrayTM”, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers. In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative disease and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit. Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. With approximately 3,000 employees worldwide, MedImmune is dedicated to advancing science and medicine to help people live better lives and is wholly owned by AstraZeneca, plc (LSE: AZN.L, NYSE: AZN). MedImmune's initial success was driven by the introduction of two generations of antibodies to prevent respiratory syncytial virus (RSV). The first was RespiGamà ® (respiratory syncytial virus immune globulin intravenous (human)), a polyclonal antibody introduced in 1996, followed in 1998 by Synagisà ® (palivizumab), a monoclonal antibody. A third-generation antibody is now in clinical testing that may have the potential to further improve upon the profile established by Synagis in helping to prevent hospitalizations due to RSV in high-risk infants. In other areas of infectious disease, MedImmune recently received FDA approval for the refrigerated formulation of FluMist (Influenza Virus Vaccine Live, Intranasal), the first innovation in flu prevention technology in more than 60 years. MedImmune's biologics pipeline has more than doubled in size to contain approxiamtely 100 research projects and more than a dozen clinical product candidates following its acquisition by AstraZeneca plc in 2007. The company also has a stronger and more diverse discovery engine with access to a wider range of cutting-edge technologies. MedImmune: Advancing science for better health� �

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

Otsuka's roots date back to 1921, when Busaburo Otsuka founded the original Otsuka Factory in Tokushima, Japan. In 1964, Otsuka Pharmaceutical Co, Ltd. (OPC) was established to enhance Otsuka's pharmaceutical product development and commercialization. The company has since grown and diversified, investing in local enterprises and establishing corporations in 17 countries and regions around the world. These comprise the Otsuka Pharmaceutical Group, a collection of 99 companies employing more than 31,000 people. In 1985, Otsuka established its first healthcare-related business in the U.S., in the Shady Grove Life Sciences Center in Montgomery County, Maryland. As the business grew, it added clinical research to its R&D capabilities, and in 1989, when the commercialization phase for products began, was incorporated as Otsuka America Pharmaceutical, Inc. (OAPI). OAPI's primary mission is to market and sell Otsuka-discovered and developed compounds, along with other pharmaceutical products and devices in the U.S. that are in parallel with our corporate business objectives. OAPI's product portfolio of marketed products is focused primarily in the areas of cardiovascular and neuroscience treatments. OAPI is also developing products for FDA review in the US, in therapeutic areas including gastrointestinal and antiseptic disease treatments. The name "Otsuka" translates to "major milestone". And indeed, in its 80 years, Otsuka's people - physicians, scientists, researchers, sales and marketing professionals, and numerous other employees - have achieved many major milestones in their mutual quest to create ethical and effective products to improve health and the quality of life for people around the world. Otsuka - people creating new products for better health worldwide.

NAMES OF COMPANIES ADDRESS

PHONE NUMBER WEBSITE NUMBER OF STAFF

ANNUAL SALES EMAIL

DESCRIPTION OF INDUSTRY

Industry Name # of Staffs Annual Earnings Address

Hospital Emergency Medicine Association 53

Gastroenterology Capital Gastroenterology 25

Shady Grove Fertility 16

Cardiac Associates 15

Internal Medicine Physician Associates 18

Urological Surgery Urological Consultants 18

Internal Medicine Food & Drug Administration 17

Pediatric Pediatric Center of Fredrick 20

Psychiatry Critical Care-NTL Inst of Hlth 29

National Institutes of Health 25

Internal Medicine Physician Associates 18

1300 Piccard Dr #202, Rockville, MD 20850-4697

15005 Shady Grove Rd., # 310, Rockville, MD 20850-6374

Reproductive Endrocrinology

15001 Shady Grove Rd., #400, Rockville, MD 20850-6320

Cardiovascular Disease

15225 Shady Grove Rd, #201

6000 Executive Blvd., #300, Rockville, MD 20852-3803

6000 Executive Blvd., #300, Rockville, MD 20852-3803

1401 Rockville 2-1428ike, Rockville MD 208

1475 Taney Ave #201, Frederick MD, 21702-5126

10 Center Dr Msc 1881, Bethesda, MD 20892-0001

Pediatric Hermatology-Oncology

10 Center Dr Msc 1928, Bethesda, MD 20892-0001

5550 Friendship Blvd, Chevy Chase, MD 20815-7256

Email Phone Website

301-921-7900

Butler, James A 301-279-2255

Vicki Gerber 301-340-1188

301-670-3000

Goldstein, Elliot R 301-468-8999

Immergut, Mark A 301-468-8999

Niu, Manette T 301-443-1544

Bromberg, David I 301-662-0133

Carter, Melody C 301-496-9320

Helman, Lee 301-402-2592

Schulman, Joel R 301-468-8999

Allen III, Yorke / Annulis, Thomas M